| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | transcription coregulator activity | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 IRF2BPL ARID1B KMT2D MAML2 ATN1 CREBBP MAML3 MED12 | 1.72e-11 | 562 | 38 | 13 | GO:0003712 |
| GeneOntologyMolecularFunction | chromatin binding | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B RUNX2 SATB1 EP400 NFAT5 ATXN1 CREBBP AR MED12 PHC1 | 3.39e-11 | 739 | 38 | 14 | GO:0003682 |
| GeneOntologyMolecularFunction | transcription coactivator activity | SMARCA2 NCOA3 NCOA6 ARID1B KMT2D MAML2 ATN1 CREBBP MAML3 MED12 | 1.81e-10 | 303 | 38 | 10 | GO:0003713 |
| GeneOntologyMolecularFunction | transcription factor binding | NCOA3 NCOR2 NCOA6 RUNX2 SATB1 FOXP2 NFAT5 CREBBP AR MED12 HTT TBP | 8.32e-09 | 753 | 38 | 12 | GO:0008134 |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 IRF2BPL ARID1B KMT2D MAML2 ATN1 CREBBP MAML3 AR MED12 | 1.20e-08 | 1160 | 38 | 14 | GO:0030674 |
| GeneOntologyMolecularFunction | RNA polymerase II transcription regulatory region sequence-specific DNA binding | NCOA3 ZNF384 POU3F2 ZFHX3 USF3 RUNX2 SATB1 FOXP2 VEZF1 NFAT5 CREBBP AR MED12 TBP THAP11 | 2.61e-08 | 1459 | 38 | 15 | GO:0000977 |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity, RNA polymerase II-specific | 6.48e-08 | 560 | 38 | 10 | GO:0001228 | |
| GeneOntologyMolecularFunction | DNA-binding transcription activator activity | 7.15e-08 | 566 | 38 | 10 | GO:0001216 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 IRF2BPL ARID1B KMT2D MAML2 ATN1 CREBBP MAML3 AR MED12 | 8.54e-08 | 1356 | 38 | 14 | GO:0060090 |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 9.28e-08 | 582 | 38 | 10 | GO:0140297 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 9.55e-07 | 417 | 38 | 8 | GO:0061629 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor activity, RNA polymerase II-specific | NCOA3 ZNF384 POU3F2 ZFHX3 KMT2D USF3 RUNX2 SATB1 FOXP2 VEZF1 NFAT5 AR THAP11 | 1.06e-06 | 1412 | 38 | 13 | GO:0000981 |
| GeneOntologyMolecularFunction | nuclear receptor binding | 1.34e-06 | 187 | 38 | 6 | GO:0016922 | |
| GeneOntologyMolecularFunction | protein domain specific binding | 3.83e-06 | 875 | 38 | 10 | GO:0019904 | |
| GeneOntologyMolecularFunction | general transcription initiation factor binding | 6.53e-06 | 64 | 38 | 4 | GO:0140296 | |
| GeneOntologyMolecularFunction | basal RNA polymerase II transcription machinery binding | 7.38e-06 | 66 | 38 | 4 | GO:0001099 | |
| GeneOntologyMolecularFunction | basal transcription machinery binding | 7.38e-06 | 66 | 38 | 4 | GO:0001098 | |
| GeneOntologyMolecularFunction | peroxisome proliferator activated receptor binding | 8.26e-06 | 21 | 38 | 3 | GO:0042975 | |
| GeneOntologyMolecularFunction | RNA polymerase II cis-regulatory region sequence-specific DNA binding | ZNF384 POU3F2 ZFHX3 RUNX2 SATB1 FOXP2 NFAT5 AR MED12 TBP THAP11 | 1.32e-05 | 1244 | 38 | 11 | GO:0000978 |
| GeneOntologyMolecularFunction | cis-regulatory region sequence-specific DNA binding | ZNF384 POU3F2 ZFHX3 RUNX2 SATB1 FOXP2 NFAT5 AR MED12 TBP THAP11 | 1.62e-05 | 1271 | 38 | 11 | GO:0000987 |
| GeneOntologyMolecularFunction | RNA polymerase II general transcription initiation factor binding | 1.80e-05 | 27 | 38 | 3 | GO:0001091 | |
| GeneOntologyMolecularFunction | nuclear androgen receptor binding | 3.33e-05 | 33 | 38 | 3 | GO:0050681 | |
| GeneOntologyMolecularFunction | nuclear thyroid hormone receptor binding | 3.65e-05 | 34 | 38 | 3 | GO:0046966 | |
| GeneOntologyMolecularFunction | TFIIB-class transcription factor binding | 5.26e-05 | 6 | 38 | 2 | GO:0001093 | |
| GeneOntologyMolecularFunction | nuclear receptor coactivator activity | 2.12e-04 | 61 | 38 | 3 | GO:0030374 | |
| GeneOntologyMolecularFunction | nuclear vitamin D receptor binding | 5.29e-04 | 18 | 38 | 2 | GO:0042809 | |
| GeneOntologyMolecularFunction | nuclear glucocorticoid receptor binding | 6.56e-04 | 20 | 38 | 2 | GO:0035259 | |
| GeneOntologyMolecularFunction | nuclear retinoid X receptor binding | 8.70e-04 | 23 | 38 | 2 | GO:0046965 | |
| GeneOntologyMolecularFunction | transcription corepressor activity | 9.16e-04 | 229 | 38 | 4 | GO:0003714 | |
| GeneOntologyMolecularFunction | ATP-dependent chromatin remodeler activity | 2.25e-03 | 37 | 38 | 2 | GO:0140658 | |
| GeneOntologyMolecularFunction | bHLH transcription factor binding | 2.25e-03 | 37 | 38 | 2 | GO:0043425 | |
| GeneOntologyMolecularFunction | transcription coregulator binding | 2.38e-03 | 140 | 38 | 3 | GO:0001221 | |
| GeneOntologyMolecularFunction | disordered domain specific binding | 2.50e-03 | 39 | 38 | 2 | GO:0097718 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity, RNA polymerase II-specific | 3.11e-03 | 320 | 38 | 4 | GO:0001227 | |
| GeneOntologyMolecularFunction | DNA-binding transcription repressor activity | 3.32e-03 | 326 | 38 | 4 | GO:0001217 | |
| GeneOntologyMolecularFunction | histone acetyltransferase activity | 4.24e-03 | 51 | 38 | 2 | GO:0004402 | |
| GeneOntologyMolecularFunction | nuclear estrogen receptor binding | 4.57e-03 | 53 | 38 | 2 | GO:0030331 | |
| GeneOntologyMolecularFunction | transcription coactivator binding | 4.74e-03 | 54 | 38 | 2 | GO:0001223 | |
| GeneOntologyMolecularFunction | peptide-lysine-N-acetyltransferase activity | 4.91e-03 | 55 | 38 | 2 | GO:0061733 | |
| GeneOntologyMolecularFunction | nuclear retinoic acid receptor binding | 4.91e-03 | 55 | 38 | 2 | GO:0042974 | |
| GeneOntologyMolecularFunction | peptide N-acetyltransferase activity | 5.82e-03 | 60 | 38 | 2 | GO:0034212 | |
| GeneOntologyMolecularFunction | histone modifying activity | 9.35e-03 | 229 | 38 | 3 | GO:0140993 | |
| GeneOntologyMolecularFunction | p53 binding | 9.43e-03 | 77 | 38 | 2 | GO:0002039 | |
| GeneOntologyMolecularFunction | N-acetyltransferase activity | 9.67e-03 | 78 | 38 | 2 | GO:0008080 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription by RNA polymerase II | MED15 SMARCA2 NCOA3 ZNF384 POU3F2 NCOA6 IRF2BPL ZFHX3 KMT2D USF3 MAML2 RUNX2 VEZF1 NFAT5 ATXN1 CREBBP MAML3 AR MED12 TBP THAP11 | 2.06e-15 | 1390 | 38 | 21 | GO:0045944 |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription | SMARCA2 NCOR2 IRF2BPL ZFHX3 RUNX2 ATN1 SATB1 FOXP2 ATXN1 CREBBP AR PHC1 THAP11 | 6.64e-07 | 1399 | 38 | 13 | GO:0045892 |
| GeneOntologyBiologicalProcess | negative regulation of RNA biosynthetic process | SMARCA2 NCOR2 IRF2BPL ZFHX3 RUNX2 ATN1 SATB1 FOXP2 ATXN1 CREBBP AR PHC1 THAP11 | 7.43e-07 | 1413 | 38 | 13 | GO:1902679 |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | MED15 SMARCA2 NCOA3 ARID1B KMT2D SATB1 EP400 NFAT5 CREBBP PHC1 TBP | 1.17e-06 | 999 | 38 | 11 | GO:0071824 |
| GeneOntologyBiologicalProcess | positive regulation of intracellular estrogen receptor signaling pathway | 1.25e-06 | 12 | 38 | 3 | GO:0033148 | |
| GeneOntologyBiologicalProcess | negative regulation of transcription by RNA polymerase II | SMARCA2 NCOR2 IRF2BPL ZFHX3 ATN1 SATB1 FOXP2 ATXN1 CREBBP AR THAP11 | 1.96e-06 | 1053 | 38 | 11 | GO:0000122 |
| GeneOntologyBiologicalProcess | positive regulation of intracellular steroid hormone receptor signaling pathway | 4.62e-06 | 18 | 38 | 3 | GO:0033145 | |
| GeneOntologyBiologicalProcess | chromatin remodeling | 6.07e-06 | 741 | 38 | 9 | GO:0006338 | |
| GeneOntologyBiologicalProcess | regulation of intracellular steroid hormone receptor signaling pathway | 1.95e-05 | 87 | 38 | 4 | GO:0033143 | |
| GeneOntologyBiologicalProcess | positive regulation of double-strand break repair | 2.76e-05 | 95 | 38 | 4 | GO:2000781 | |
| GeneOntologyBiologicalProcess | chromatin organization | 2.77e-05 | 896 | 38 | 9 | GO:0006325 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated signaling pathway | 3.31e-05 | 202 | 38 | 5 | GO:0141193 | |
| GeneOntologyBiologicalProcess | head development | 3.38e-05 | 919 | 38 | 9 | GO:0060322 | |
| GeneOntologyBiologicalProcess | regulation of intracellular estrogen receptor signaling pathway | 3.95e-05 | 36 | 38 | 3 | GO:0033146 | |
| GeneOntologyBiologicalProcess | central nervous system development | 4.43e-05 | 1197 | 38 | 10 | GO:0007417 | |
| GeneOntologyBiologicalProcess | cell proliferation in forebrain | 4.65e-05 | 38 | 38 | 3 | GO:0021846 | |
| GeneOntologyBiologicalProcess | DNA-templated transcription initiation | 6.26e-05 | 231 | 38 | 5 | GO:0006352 | |
| GeneOntologyBiologicalProcess | vocal learning | 6.90e-05 | 7 | 38 | 2 | GO:0042297 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription of Notch receptor target | 6.90e-05 | 7 | 38 | 2 | GO:0007221 | |
| GeneOntologyBiologicalProcess | imitative learning | 6.90e-05 | 7 | 38 | 2 | GO:0098596 | |
| GeneOntologyBiologicalProcess | stem cell population maintenance | 7.07e-05 | 237 | 38 | 5 | GO:0019827 | |
| GeneOntologyBiologicalProcess | maintenance of cell number | 7.81e-05 | 242 | 38 | 5 | GO:0098727 | |
| GeneOntologyBiologicalProcess | hormone-mediated signaling pathway | 8.11e-05 | 244 | 38 | 5 | GO:0009755 | |
| GeneOntologyBiologicalProcess | multicellular organism growth | 8.93e-05 | 249 | 38 | 5 | GO:0035264 | |
| GeneOntologyBiologicalProcess | nuclear receptor-mediated steroid hormone signaling pathway | 1.12e-04 | 136 | 38 | 4 | GO:0030518 | |
| GeneOntologyBiologicalProcess | observational learning | 1.18e-04 | 9 | 38 | 2 | GO:0098597 | |
| GeneOntologyBiologicalProcess | positive regulation of myoblast differentiation | 1.34e-04 | 54 | 38 | 3 | GO:0045663 | |
| GeneOntologyBiologicalProcess | positive regulation of DNA repair | 1.36e-04 | 143 | 38 | 4 | GO:0045739 | |
| GeneOntologyBiologicalProcess | brain development | 1.41e-04 | 859 | 38 | 8 | GO:0007420 | |
| GeneOntologyBiologicalProcess | development of secondary female sexual characteristics | 1.47e-04 | 10 | 38 | 2 | GO:0046543 | |
| GeneOntologyBiologicalProcess | regulation of double-strand break repair | 1.47e-04 | 146 | 38 | 4 | GO:2000779 | |
| GeneOntologyBiologicalProcess | estrogen receptor signaling pathway | 1.58e-04 | 57 | 38 | 3 | GO:0030520 | |
| GeneOntologyBiologicalProcess | positive regulation of cell differentiation | 1.78e-04 | 1141 | 38 | 9 | GO:0045597 | |
| GeneOntologyBiologicalProcess | learned vocalization behavior or vocal learning | 1.80e-04 | 11 | 38 | 2 | GO:0098598 | |
| GeneOntologyBiologicalProcess | steroid hormone receptor signaling pathway | 1.86e-04 | 155 | 38 | 4 | GO:0043401 | |
| GeneOntologyBiologicalProcess | chordate embryonic development | 2.03e-04 | 906 | 38 | 8 | GO:0043009 | |
| GeneOntologyBiologicalProcess | embryo development | 2.03e-04 | 1437 | 38 | 10 | GO:0009790 | |
| GeneOntologyBiologicalProcess | embryo development ending in birth or egg hatching | 2.41e-04 | 929 | 38 | 8 | GO:0009792 | |
| GeneOntologyBiologicalProcess | development of secondary sexual characteristics | 2.55e-04 | 13 | 38 | 2 | GO:0045136 | |
| GeneOntologyBiologicalProcess | positive regulation of transcription initiation by RNA polymerase II | 2.90e-04 | 70 | 38 | 3 | GO:0060261 | |
| GeneOntologyBiologicalProcess | auditory behavior | 2.97e-04 | 14 | 38 | 2 | GO:0031223 | |
| GeneOntologyBiologicalProcess | growth | 3.22e-04 | 1235 | 38 | 9 | GO:0040007 | |
| GeneOntologyBiologicalProcess | telencephalon development | 3.40e-04 | 332 | 38 | 5 | GO:0021537 | |
| GeneOntologyBiologicalProcess | transcription initiation at RNA polymerase II promoter | 3.72e-04 | 186 | 38 | 4 | GO:0006367 | |
| GeneOntologyBiologicalProcess | positive regulation of DNA-templated transcription initiation | 3.84e-04 | 77 | 38 | 3 | GO:2000144 | |
| GeneOntologyBiologicalProcess | mechanosensory behavior | 4.42e-04 | 17 | 38 | 2 | GO:0007638 | |
| GeneOntologyBiologicalProcess | regulation of transcription initiation by RNA polymerase II | 4.46e-04 | 81 | 38 | 3 | GO:0060260 | |
| GeneOntologyBiologicalProcess | cerebellar Purkinje cell differentiation | 4.96e-04 | 18 | 38 | 2 | GO:0021702 | |
| GeneOntologyBiologicalProcess | cerebellar Purkinje cell layer formation | 6.15e-04 | 20 | 38 | 2 | GO:0021694 | |
| GeneOntologyBiologicalProcess | regulation of DNA-templated transcription initiation | 6.27e-04 | 91 | 38 | 3 | GO:2000142 | |
| GeneOntologyBiologicalProcess | regulation of myoblast differentiation | 6.47e-04 | 92 | 38 | 3 | GO:0045661 | |
| GeneOntologyBiologicalProcess | striatum development | 7.46e-04 | 22 | 38 | 2 | GO:0021756 | |
| GeneOntologyBiologicalProcess | cellular response to organic cyclic compound | 7.71e-04 | 605 | 38 | 6 | GO:0071407 | |
| GeneOntologyBiologicalProcess | regulation of DNA repair | 8.80e-04 | 234 | 38 | 4 | GO:0006282 | |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 9.45e-04 | 416 | 38 | 5 | GO:0030522 | |
| GeneOntologyBiologicalProcess | cellular response to steroid hormone stimulus | 9.52e-04 | 239 | 38 | 4 | GO:0071383 | |
| GeneOntologyBiologicalProcess | cerebellar Purkinje cell layer morphogenesis | 9.65e-04 | 25 | 38 | 2 | GO:0021692 | |
| GeneOntologyBiologicalProcess | regulation of cell cycle G1/S phase transition | 1.06e-03 | 246 | 38 | 4 | GO:1902806 | |
| GeneOntologyBiologicalProcess | subpallium development | 1.21e-03 | 28 | 38 | 2 | GO:0021544 | |
| GeneOntologyBiologicalProcess | developmental growth | 1.22e-03 | 911 | 38 | 7 | GO:0048589 | |
| GeneOntologyBiologicalProcess | regulation of nucleotide-excision repair | 1.30e-03 | 29 | 38 | 2 | GO:2000819 | |
| GeneOntologyBiologicalProcess | regulation of insulin-like growth factor receptor signaling pathway | 1.30e-03 | 29 | 38 | 2 | GO:0043567 | |
| GeneOntologyBiologicalProcess | branching involved in mammary gland duct morphogenesis | 1.39e-03 | 30 | 38 | 2 | GO:0060444 | |
| GeneOntologyBiologicalProcess | reflex | 1.49e-03 | 31 | 38 | 2 | GO:0060004 | |
| GeneOntologyBiologicalProcess | developmental process involved in reproduction | 1.58e-03 | 1235 | 38 | 8 | GO:0003006 | |
| GeneOntologyBiologicalProcess | cell differentiation in hindbrain | 1.58e-03 | 32 | 38 | 2 | GO:0021533 | |
| GeneOntologyBiologicalProcess | positive regulation of signaling receptor activity | 1.68e-03 | 33 | 38 | 2 | GO:2000273 | |
| GeneOntologyBiologicalProcess | cerebellar cortex formation | 1.79e-03 | 34 | 38 | 2 | GO:0021697 | |
| GeneOntologyBiologicalProcess | embryonic morphogenesis | 1.79e-03 | 713 | 38 | 6 | GO:0048598 | |
| GeneOntologyBiologicalProcess | forebrain development | 1.93e-03 | 489 | 38 | 5 | GO:0030900 | |
| GeneOntologyBiologicalProcess | cellular response to hormone stimulus | 1.98e-03 | 727 | 38 | 6 | GO:0032870 | |
| GeneOntologyBiologicalProcess | myoblast differentiation | 2.00e-03 | 136 | 38 | 3 | GO:0045445 | |
| GeneOntologyBiologicalProcess | response to auditory stimulus | 2.11e-03 | 37 | 38 | 2 | GO:0010996 | |
| GeneOntologyBiologicalProcess | cerebellum development | 2.13e-03 | 139 | 38 | 3 | GO:0021549 | |
| GeneOntologyBiologicalProcess | cellular response to lipid | 2.28e-03 | 748 | 38 | 6 | GO:0071396 | |
| GeneOntologyBiologicalProcess | cerebellar Purkinje cell layer development | 2.35e-03 | 39 | 38 | 2 | GO:0021680 | |
| GeneOntologyBiologicalProcess | cell cycle G1/S phase transition | 2.36e-03 | 306 | 38 | 4 | GO:0044843 | |
| GeneOntologyBiologicalProcess | response to hormone | 2.62e-03 | 1042 | 38 | 7 | GO:0009725 | |
| GeneOntologyBiologicalProcess | response to organic cyclic compound | 2.71e-03 | 1048 | 38 | 7 | GO:0014070 | |
| GeneOntologyBiologicalProcess | regulation of G0 to G1 transition | 2.72e-03 | 42 | 38 | 2 | GO:0070316 | |
| GeneOntologyBiologicalProcess | metencephalon development | 2.79e-03 | 153 | 38 | 3 | GO:0022037 | |
| GeneOntologyBiologicalProcess | double-strand break repair | 2.90e-03 | 324 | 38 | 4 | GO:0006302 | |
| GeneOntologyBiologicalProcess | positive regulation of double-strand break repair via homologous recombination | 2.98e-03 | 44 | 38 | 2 | GO:1905168 | |
| GeneOntologyBiologicalProcess | G0 to G1 transition | 2.98e-03 | 44 | 38 | 2 | GO:0045023 | |
| GeneOntologyBiologicalProcess | mammary gland duct morphogenesis | 3.11e-03 | 45 | 38 | 2 | GO:0060603 | |
| GeneOntologyBiologicalProcess | positive regulation of DNA metabolic process | 3.20e-03 | 333 | 38 | 4 | GO:0051054 | |
| GeneOntologyBiologicalProcess | mammary gland development | 3.28e-03 | 162 | 38 | 3 | GO:0030879 | |
| GeneOntologyBiologicalProcess | Schwann cell development | 3.39e-03 | 47 | 38 | 2 | GO:0014044 | |
| GeneOntologyBiologicalProcess | cerebellar cortex morphogenesis | 3.53e-03 | 48 | 38 | 2 | GO:0021696 | |
| GeneOntologyCellularComponent | chromatin | SMARCA2 NCOA3 NCOR2 POU3F2 ZFHX3 ARID1B RUNX2 SATB1 EP400 FOXP2 NFAT5 CREBBP AR PHC1 TBP THAP11 | 2.91e-09 | 1480 | 39 | 16 | GO:0000785 |
| GeneOntologyCellularComponent | transcription regulator complex | MED15 NCOA3 NCOR2 POU3F2 NCOA6 ZFHX3 RUNX2 NFAT5 CREBBP TBP THAP11 | 7.49e-09 | 596 | 39 | 11 | GO:0005667 |
| GeneOntologyCellularComponent | nuclear protein-containing complex | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D EP400 CREBBP MED12 PHC1 TBP THAP11 | 6.70e-07 | 1377 | 39 | 13 | GO:0140513 |
| GeneOntologyCellularComponent | nuclear body | 4.37e-06 | 903 | 39 | 10 | GO:0016604 | |
| GeneOntologyCellularComponent | nuclear matrix | 1.32e-04 | 140 | 39 | 4 | GO:0016363 | |
| GeneOntologyCellularComponent | RNA polymerase II transcription regulator complex | 1.44e-04 | 272 | 39 | 5 | GO:0090575 | |
| GeneOntologyCellularComponent | bBAF complex | 1.51e-04 | 10 | 39 | 2 | GO:0140092 | |
| GeneOntologyCellularComponent | MLL3/4 complex | 2.21e-04 | 12 | 39 | 2 | GO:0044666 | |
| GeneOntologyCellularComponent | nuclear periphery | 2.84e-04 | 171 | 39 | 4 | GO:0034399 | |
| GeneOntologyCellularComponent | npBAF complex | 3.04e-04 | 14 | 39 | 2 | GO:0071564 | |
| GeneOntologyCellularComponent | brahma complex | 3.04e-04 | 14 | 39 | 2 | GO:0035060 | |
| GeneOntologyCellularComponent | nBAF complex | 4.00e-04 | 16 | 39 | 2 | GO:0071565 | |
| GeneOntologyCellularComponent | SWI/SNF superfamily-type complex | 7.61e-04 | 96 | 39 | 3 | GO:0070603 | |
| GeneOntologyCellularComponent | nuclear speck | 1.18e-03 | 431 | 39 | 5 | GO:0016607 | |
| GeneOntologyCellularComponent | SWI/SNF complex | 1.43e-03 | 30 | 39 | 2 | GO:0016514 | |
| GeneOntologyCellularComponent | ATPase complex | 1.78e-03 | 129 | 39 | 3 | GO:1904949 | |
| GeneOntologyCellularComponent | transferase complex | 1.82e-03 | 963 | 39 | 7 | GO:1990234 | |
| HumanPheno | Prominent fingertip pads | 2.59e-08 | 46 | 22 | 6 | HP:0001212 | |
| HumanPheno | Prominent digit pad | 3.38e-08 | 48 | 22 | 6 | HP:0011298 | |
| HumanPheno | Progressive cerebellar ataxia | 1.98e-07 | 64 | 22 | 6 | HP:0002073 | |
| HumanPheno | Cerebellar ataxia | 2.85e-07 | 68 | 22 | 6 | HP:0001253 | |
| HumanPheno | Abnormality of ocular smooth pursuit | 4.75e-07 | 74 | 22 | 6 | HP:0000617 | |
| HumanPheno | Abnormal esophagus physiology | SMARCA2 IRF2BPL KMT2D ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP AR MED12 HTT TBP | 3.23e-06 | 933 | 22 | 14 | HP:0025270 |
| HumanPheno | Genetic anticipation | 5.78e-06 | 9 | 22 | 3 | HP:0003743 | |
| HumanPheno | Functional abnormality of the bladder | SMARCA2 KMT2D SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP MED12 PHC1 TBP | 9.75e-06 | 590 | 22 | 11 | HP:0000009 |
| HumanPheno | Dysarthria | IRF2BPL ZFHX3 KMT2D ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 AR TBP | 1.37e-05 | 611 | 22 | 11 | HP:0001260 |
| HumanPheno | Narrow palate | 1.43e-05 | 202 | 22 | 7 | HP:0000189 | |
| HumanPheno | Abnormal fingertip morphology | 1.47e-05 | 203 | 22 | 7 | HP:0001211 | |
| HumanPheno | Abnormality of the bladder | SMARCA2 KMT2D SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP MED12 PHC1 TBP | 1.61e-05 | 621 | 22 | 11 | HP:0000014 |
| HumanPheno | Cerebellar Purkinje layer atrophy | 1.78e-05 | 2 | 22 | 2 | HP:0012082 | |
| HumanPheno | Aplasia/Hypoplasia of the distal phalanx of the 5th toe | 1.78e-05 | 2 | 22 | 2 | HP:0100371 | |
| HumanPheno | Abnormality of the distal phalanx of the 5th toe | 1.78e-05 | 2 | 22 | 2 | HP:0010392 | |
| HumanPheno | Abnormal esophagus morphology | SMARCA2 IRF2BPL KMT2D ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP AR MED12 HTT TBP | 1.91e-05 | 1078 | 22 | 14 | HP:0002031 |
| HumanPheno | Functional abnormality of the gastrointestinal tract | SMARCA2 IRF2BPL ARID1B KMT2D ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP AR MED12 HTT TBP | 2.28e-05 | 1270 | 22 | 15 | HP:0012719 |
| HumanPheno | Abnormality of the lower urinary tract | SMARCA2 ARID1B KMT2D SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP AR MED12 PHC1 TBP | 2.44e-05 | 937 | 22 | 13 | HP:0010936 |
| HumanPheno | Impaired smooth pursuit | 2.62e-05 | 42 | 22 | 4 | HP:0007772 | |
| HumanPheno | Thick eyebrow | 3.46e-05 | 154 | 22 | 6 | HP:0000574 | |
| HumanPheno | Limb ataxia | 3.56e-05 | 92 | 22 | 5 | HP:0002070 | |
| HumanPheno | High, narrow palate | 3.72e-05 | 156 | 22 | 6 | HP:0002705 | |
| HumanPheno | Abnormality of proprioception | 3.86e-05 | 157 | 22 | 6 | HP:0010870 | |
| HumanPheno | Impaired proprioception | 3.86e-05 | 157 | 22 | 6 | HP:0010831 | |
| HumanPheno | Feeding difficulties | IRF2BPL ARID1B KMT2D ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP AR HTT TBP | 4.13e-05 | 982 | 22 | 13 | HP:0002022 |
| HumanPheno | Dysphagia | 5.02e-05 | 567 | 22 | 10 | HP:0002015 | |
| HumanPheno | Dysmetric saccades | 5.47e-05 | 18 | 22 | 3 | HP:0000641 | |
| HumanPheno | Dimple chin | 5.47e-05 | 18 | 22 | 3 | HP:0010751 | |
| HumanPheno | Gait ataxia | 7.89e-05 | 263 | 22 | 7 | HP:0002066 | |
| HumanPheno | Dysmetria | 8.08e-05 | 179 | 22 | 6 | HP:0001310 | |
| HumanPheno | Low hanging columella | 8.27e-05 | 56 | 22 | 4 | HP:0009765 | |
| HumanPheno | Abnormality of coordination | SMARCA2 IRF2BPL ZFHX3 ARID1B USF3 ATN1 SATB1 FOXP2 ATXN1 ATXN2 ATXN8 CREBBP HTT TBP | 8.98e-05 | 1227 | 22 | 14 | HP:0011443 |
| HumanPheno | Aplasia/Hypoplasia of the 5th toe | 1.06e-04 | 4 | 22 | 2 | HP:0010343 | |
| HumanPheno | Bradykinesia | 1.08e-04 | 116 | 22 | 5 | HP:0002067 | |
| HumanPheno | Abnormality of the hairline | 1.60e-04 | 294 | 22 | 7 | HP:0009553 | |
| HumanPheno | Hypoplasia of teeth | 1.61e-04 | 126 | 22 | 5 | HP:0000685 | |
| HumanPheno | High palate | SMARCA2 KCNN3 ARID1B KMT2D USF3 RUNX2 ATN1 FOXP2 MN1 CREBBP MED12 | 1.66e-04 | 794 | 22 | 11 | HP:0000218 |
| HumanPheno | Supranuclear ophthalmoplegia | 1.77e-04 | 5 | 22 | 2 | HP:0000623 | |
| HumanPheno | Aplasia/Hypoplasia of the phalanges of the 5th toe | 1.77e-04 | 5 | 22 | 2 | HP:0010383 | |
| HumanPheno | Abnormality of the phalanges of the 5th toe | 1.77e-04 | 5 | 22 | 2 | HP:0010342 | |
| HumanPheno | Long eyelashes | 1.79e-04 | 129 | 22 | 5 | HP:0000527 | |
| HumanPheno | Short phalanx of finger | 2.05e-04 | 306 | 22 | 7 | HP:0009803 | |
| HumanPheno | Aplasia/hypoplasia involving bones of the hand | 2.15e-04 | 538 | 22 | 9 | HP:0005927 | |
| HumanPheno | Abnormality of the frontal hairline | 2.23e-04 | 215 | 22 | 6 | HP:0000599 | |
| HumanPheno | Regional abnormality of skin | 2.24e-04 | 541 | 22 | 9 | HP:0011356 | |
| HumanPheno | Thick lower lip vermilion | 2.30e-04 | 136 | 22 | 5 | HP:0000179 | |
| HumanPheno | Cafe-au-lait spot | 2.38e-04 | 137 | 22 | 5 | HP:0000957 | |
| HumanPheno | Prominent interphalangeal joints | 2.64e-04 | 6 | 22 | 2 | HP:0006237 | |
| HumanPheno | Large foramen magnum | 2.64e-04 | 6 | 22 | 2 | HP:0002700 | |
| HumanPheno | Aplasia/Hypoplasia of the phalanges of the hand | 2.66e-04 | 319 | 22 | 7 | HP:0009767 | |
| HumanPheno | Thin vermilion border | 2.81e-04 | 433 | 22 | 8 | HP:0000233 | |
| HumanPheno | Absent speech | 2.94e-04 | 436 | 22 | 8 | HP:0001344 | |
| HumanPheno | Short finger | 2.98e-04 | 325 | 22 | 7 | HP:0009381 | |
| HumanPheno | Congenital abnormal hair pattern | 3.10e-04 | 327 | 22 | 7 | HP:0011361 | |
| HumanPheno | Incoordination | SMARCA2 IRF2BPL ZFHX3 ARID1B USF3 ATN1 SATB1 ATXN1 ATXN2 ATXN8 CREBBP HTT TBP | 3.17e-04 | 1184 | 22 | 13 | HP:0002311 |
| HumanPheno | Aplasia/hypoplasia involving bones of the upper limbs | 3.44e-04 | 572 | 22 | 9 | HP:0006496 | |
| HumanPheno | Coarctation of aorta | 3.64e-04 | 150 | 22 | 5 | HP:0001680 | |
| HumanPheno | Abnormal prosody | 3.66e-04 | 82 | 22 | 4 | HP:0031434 | |
| HumanPheno | Impaired horizontal smooth pursuit | 3.69e-04 | 7 | 22 | 2 | HP:0001151 | |
| HumanPheno | Thin upper lip vermilion | 3.87e-04 | 339 | 22 | 7 | HP:0000219 | |
| HumanPheno | Thin lips | 3.87e-04 | 339 | 22 | 7 | HP:0000213 | |
| HumanPheno | Supernumerary tooth | 4.20e-04 | 85 | 22 | 4 | HP:0011069 | |
| HumanPheno | Prominent lips | 4.36e-04 | 156 | 22 | 5 | HP:0000184 | |
| HumanPheno | Deficiency of speech development | 4.45e-04 | 463 | 22 | 8 | HP:0002116 | |
| HumanPheno | Nasolacrimal duct obstruction | 4.55e-04 | 36 | 22 | 3 | HP:0000579 | |
| HumanPheno | Broad toe | 4.59e-04 | 87 | 22 | 4 | HP:0001837 | |
| HumanPheno | Cerebellar atrophy | 4.79e-04 | 468 | 22 | 8 | HP:0001272 | |
| HumanPheno | Chorea | 4.84e-04 | 248 | 22 | 6 | HP:0002072 | |
| HumanPheno | Long thumb | 4.91e-04 | 8 | 22 | 2 | HP:0032524 | |
| HumanPheno | Atrophy/Degeneration affecting the cerebellum | 4.93e-04 | 470 | 22 | 8 | HP:0007368 | |
| HumanPheno | Drooling | 5.04e-04 | 161 | 22 | 5 | HP:0002307 | |
| HumanPheno | Abnormally folded helix | 5.23e-04 | 90 | 22 | 4 | HP:0008544 | |
| HumanPheno | Ataxia | SMARCA2 IRF2BPL ZFHX3 ARID1B USF3 ATN1 SATB1 ATXN1 ATXN2 ATXN8 HTT TBP | 5.61e-04 | 1073 | 22 | 12 | HP:0001251 |
| HumanPheno | Thick nasal alae | 5.78e-04 | 39 | 22 | 3 | HP:0009928 | |
| HumanPheno | Postural instability | 5.92e-04 | 93 | 22 | 4 | HP:0002172 | |
| HumanPheno | Aplasia/Hypoplasia of fingers | 6.18e-04 | 366 | 22 | 7 | HP:0006265 | |
| HumanPheno | Abnormality of the palmar creases | 6.23e-04 | 260 | 22 | 6 | HP:0010490 | |
| HumanPheno | Neuronal loss in central nervous system | 6.23e-04 | 40 | 22 | 3 | HP:0002529 | |
| HumanPheno | Cerebellar malformation | 6.28e-04 | 487 | 22 | 8 | HP:0002438 | |
| HumanPheno | Clinodactyly of the 2nd finger | 6.29e-04 | 9 | 22 | 2 | HP:0040022 | |
| HumanPheno | Pilomatrixoma | 6.29e-04 | 9 | 22 | 2 | HP:0030434 | |
| HumanPheno | Excessive salivation | 6.48e-04 | 170 | 22 | 5 | HP:0003781 | |
| HumanPheno | Abnormal nasal dorsum morphology | 6.49e-04 | 262 | 22 | 6 | HP:0011119 | |
| HumanPheno | Sandal gap | 6.68e-04 | 96 | 22 | 4 | HP:0001852 | |
| HumanPheno | Abnormal palmar dermatoglyphics | 6.89e-04 | 265 | 22 | 6 | HP:0001018 | |
| HumanPheno | Abnormal columella morphology | 6.95e-04 | 97 | 22 | 4 | HP:0009929 | |
| HumanPheno | Skin tags | 6.95e-04 | 97 | 22 | 4 | HP:0010609 | |
| HumanPheno | Slow saccadic eye movements | 7.20e-04 | 42 | 22 | 3 | HP:0000514 | |
| HumanPheno | Downslanted palpebral fissures | 7.21e-04 | 497 | 22 | 8 | HP:0000494 | |
| HumanPheno | Abnormal 2nd finger morphology | 7.72e-04 | 43 | 22 | 3 | HP:0004100 | |
| HumanPheno | Congenital diaphragmatic hernia | 7.79e-04 | 100 | 22 | 4 | HP:0000776 | |
| HumanPheno | Sensory neuropathy | 7.81e-04 | 503 | 22 | 8 | HP:0000763 | |
| HumanPheno | Patent ductus arteriosus | 8.01e-04 | 382 | 22 | 7 | HP:0001643 | |
| HumanPheno | Meningioma | 8.26e-04 | 44 | 22 | 3 | HP:0002858 | |
| HumanPheno | Cleft palate | 8.30e-04 | 643 | 22 | 9 | HP:0000175 | |
| HumanPheno | Abnormal hard palate morphology | 8.69e-04 | 647 | 22 | 9 | HP:0100737 | |
| HumanPheno | Abnormal involuntary eye movements | IRF2BPL ARID1B KMT2D ATN1 ATXN1 ATXN2 ATXN8 MN1 CREBBP MED12 HTT TBP | 8.69e-04 | 1123 | 22 | 12 | HP:0012547 |
| HumanPheno | Broad philtrum | 8.82e-04 | 45 | 22 | 3 | HP:0000289 | |
| HumanPheno | Enamel hypoplasia | 9.04e-04 | 104 | 22 | 4 | HP:0006297 | |
| HumanPheno | Smooth philtrum | 9.52e-04 | 185 | 22 | 5 | HP:0000319 | |
| MousePheno | lethality during fetal growth through weaning, complete penetrance | NCOR2 POU3F2 NCOA6 ARID1B RUNX2 SATB1 FOXP2 VEZF1 NFAT5 MN1 CREBBP PHC1 HTT THAP11 | 3.77e-07 | 1269 | 33 | 14 | MP:0011111 |
| MousePheno | abnormal craniofacial morphology | NCOA3 NCOR2 NCOA6 KMT2D RUNX2 FOXP2 VEZF1 MN1 CREBBP MED12 PHC1 HTT THAP11 | 6.48e-06 | 1372 | 33 | 13 | MP:0000428 |
| MousePheno | craniofacial phenotype | NCOA3 NCOR2 NCOA6 KMT2D RUNX2 FOXP2 VEZF1 MN1 CREBBP MED12 PHC1 HTT THAP11 | 6.48e-06 | 1372 | 33 | 13 | MP:0005382 |
| MousePheno | premature death | KCNN3 NCOA3 ZFHX3 RUNX2 ATN1 SATB1 FOXP2 ATXN1 CREBBP AR HTT | 1.70e-05 | 1051 | 33 | 11 | MP:0002083 |
| MousePheno | increased grooming behavior | 2.64e-05 | 74 | 33 | 4 | MP:0001441 | |
| MousePheno | abnormal postnatal growth | 2.95e-05 | 907 | 33 | 10 | MP:0001731 | |
| MousePheno | lethality during fetal growth through weaning, incomplete penetrance | 3.20e-05 | 1124 | 33 | 11 | MP:0011112 | |
| MousePheno | nasal bone hypoplasia | 3.23e-05 | 4 | 33 | 2 | MP:0000103 | |
| MousePheno | perinatal lethality | NCOA6 ARID1B RUNX2 FOXP2 VEZF1 NFAT5 MN1 CREBBP PHC1 HTT THAP11 | 3.36e-05 | 1130 | 33 | 11 | MP:0002081 |
| MousePheno | abnormal palatal shelf fusion at midline | 3.59e-05 | 80 | 33 | 4 | MP:0009887 | |
| MousePheno | abnormal craniofacial development | 4.92e-05 | 425 | 33 | 7 | MP:0003935 | |
| MousePheno | lethality throughout fetal growth and development | 5.70e-05 | 435 | 33 | 7 | MP:0006208 | |
| MousePheno | abnormal blood cell morphology/development | 6.03e-05 | 986 | 33 | 10 | MP:0002429 | |
| MousePheno | abnormal hematopoietic precursor cell morphology | 6.20e-05 | 299 | 33 | 6 | MP:0013707 | |
| MousePheno | increased liver glycogen level | 6.82e-05 | 34 | 33 | 3 | MP:0010400 | |
| MousePheno | abnormal occipital bone morphology | 7.04e-05 | 95 | 33 | 4 | MP:0005269 | |
| MousePheno | limb grasping | 9.83e-05 | 325 | 33 | 6 | MP:0001513 | |
| MousePheno | abnormal hemopoiesis | 1.01e-04 | 839 | 33 | 9 | MP:0013693 | |
| MousePheno | impaired coordination | 1.03e-04 | 478 | 33 | 7 | MP:0001405 | |
| MousePheno | postnatal growth retardation | 1.47e-04 | 881 | 33 | 9 | MP:0001732 | |
| MousePheno | large anterior fontanelle | 1.50e-04 | 8 | 33 | 2 | MP:0000085 | |
| MousePheno | abnormal anterior fontanelle morphology | 1.50e-04 | 8 | 33 | 2 | MP:0030363 | |
| MousePheno | abnormal head morphology | 1.75e-04 | 1120 | 33 | 10 | MP:0000432 | |
| MousePheno | abnormal palatal shelf morphology | 1.80e-04 | 121 | 33 | 4 | MP:0031460 | |
| MousePheno | neuronal intranuclear inclusions | 1.93e-04 | 9 | 33 | 2 | MP:0004191 | |
| MousePheno | abnormal secondary palate development | 1.98e-04 | 124 | 33 | 4 | MP:0009655 | |
| MousePheno | extramedullary hematopoiesis | 2.10e-04 | 126 | 33 | 4 | MP:0000240 | |
| MousePheno | cleft secondary palate | 2.17e-04 | 127 | 33 | 4 | MP:0009890 | |
| MousePheno | abnormal palate development | 2.30e-04 | 129 | 33 | 4 | MP:0009653 | |
| MousePheno | palatal shelves fail to meet at midline | 2.89e-04 | 55 | 33 | 3 | MP:0009888 | |
| MousePheno | abnormal grooming behavior | 2.90e-04 | 137 | 33 | 4 | MP:0001440 | |
| MousePheno | thin ventricular wall | 2.98e-04 | 138 | 33 | 4 | MP:0000280 | |
| MousePheno | facial bone hypoplasia | 3.22e-04 | 57 | 33 | 3 | MP:0030386 | |
| MousePheno | increased glycogen level | 3.22e-04 | 57 | 33 | 3 | MP:0005440 | |
| MousePheno | lethality throughout fetal growth and development, complete penetrance | 3.50e-04 | 263 | 33 | 5 | MP:0011099 | |
| MousePheno | flattened snout | 3.51e-04 | 12 | 33 | 2 | MP:0000447 | |
| MousePheno | hypoactivity | 4.50e-04 | 1023 | 33 | 9 | MP:0031392 | |
| MousePheno | abnormal bone marrow cell number | 4.52e-04 | 154 | 33 | 4 | MP:0000172 | |
| MousePheno | abnormal definitive hematopoiesis | 4.58e-04 | 808 | 33 | 8 | MP:0002123 | |
| MousePheno | abnormal adiponectin level | 4.74e-04 | 65 | 33 | 3 | MP:0004891 | |
| MousePheno | abnormal secondary palate morphology | 5.10e-04 | 159 | 33 | 4 | MP:0013550 | |
| MousePheno | abnormal brain ventricle morphology | 5.14e-04 | 286 | 33 | 5 | MP:0000822 | |
| MousePheno | abnormal myocardium compact layer morphology | 5.18e-04 | 67 | 33 | 3 | MP:0004056 | |
| MousePheno | abnormal cranial suture morphology | 5.18e-04 | 67 | 33 | 3 | MP:0002835 | |
| MousePheno | decreased locomotor activity | 5.44e-04 | 829 | 33 | 8 | MP:0001402 | |
| MousePheno | short stride length | 5.65e-04 | 69 | 33 | 3 | MP:0001407 | |
| MousePheno | decreased hormone level | 5.87e-04 | 635 | 33 | 7 | MP:0014455 | |
| MousePheno | abnormal craniofacial suture morphology | 5.89e-04 | 70 | 33 | 3 | MP:0030229 | |
| MousePheno | increased hormone level | 6.21e-04 | 641 | 33 | 7 | MP:0014454 | |
| MousePheno | small basisphenoid bone | 6.35e-04 | 16 | 33 | 2 | MP:0004462 | |
| MousePheno | large fontanelles | 6.35e-04 | 16 | 33 | 2 | MP:0030388 | |
| MousePheno | abnormal hormone level | 6.39e-04 | 1073 | 33 | 9 | MP:0003953 | |
| MousePheno | postnatal lethality | 6.88e-04 | 1084 | 33 | 9 | MP:0002082 | |
| MousePheno | abnormal susceptibility to weight gain | 7.29e-04 | 309 | 33 | 5 | MP:0011117 | |
| MousePheno | abnormal motor coordination/balance | 7.67e-04 | 873 | 33 | 8 | MP:0001516 | |
| MousePheno | lowered ear position | 8.08e-04 | 18 | 33 | 2 | MP:0000024 | |
| MousePheno | abnormal palate morphology | 8.66e-04 | 321 | 33 | 5 | MP:0003755 | |
| MousePheno | abnormal energy homeostasis | 8.78e-04 | 322 | 33 | 5 | MP:0005448 | |
| MousePheno | abnormal liver glycogen level | 9.02e-04 | 81 | 33 | 3 | MP:0012777 | |
| MousePheno | abnormal stride length | 9.35e-04 | 82 | 33 | 3 | MP:0012690 | |
| MousePheno | increased insulin sensitivity | 9.56e-04 | 188 | 33 | 4 | MP:0002891 | |
| MousePheno | decreased circulating glucagon level | 1.00e-03 | 20 | 33 | 2 | MP:0002696 | |
| MousePheno | enlarged lateral ventricles | 1.00e-03 | 84 | 33 | 3 | MP:0008535 | |
| MousePheno | perinatal lethality, incomplete penetrance | 1.02e-03 | 503 | 33 | 6 | MP:0011090 | |
| MousePheno | abnormal bone marrow cell morphology/development | 1.10e-03 | 706 | 33 | 7 | MP:0002398 | |
| MousePheno | small interparietal bone | 1.10e-03 | 21 | 33 | 2 | MP:0004384 | |
| MousePheno | perinatal lethality, complete penetrance | 1.15e-03 | 712 | 33 | 7 | MP:0011089 | |
| MousePheno | dilated brain ventricle | 1.30e-03 | 92 | 33 | 3 | MP:0012676 | |
| MousePheno | abnormal fontanelle morphology | 1.33e-03 | 23 | 33 | 2 | MP:0000084 | |
| MousePheno | lethality throughout fetal growth and development, incomplete penetrance | 1.39e-03 | 208 | 33 | 4 | MP:0011109 | |
| MousePheno | abnormal sphenoid bone morphology | 1.43e-03 | 95 | 33 | 3 | MP:0000104 | |
| MousePheno | abnormal adaptive thermogenesis | 1.47e-03 | 96 | 33 | 3 | MP:0011019 | |
| MousePheno | decreased fat cell size | 1.52e-03 | 97 | 33 | 3 | MP:0009269 | |
| MousePheno | prenatal lethality, incomplete penetrance | 1.53e-03 | 747 | 33 | 7 | MP:0011101 | |
| MousePheno | decreased circulating hormone level | 1.63e-03 | 551 | 33 | 6 | MP:0014457 | |
| MousePheno | abnormal heart development | 1.67e-03 | 372 | 33 | 5 | MP:0000267 | |
| MousePheno | abnormal limbic system morphology | 1.79e-03 | 378 | 33 | 5 | MP:0004166 | |
| MousePheno | small parietal bone | 1.83e-03 | 27 | 33 | 2 | MP:0004418 | |
| MousePheno | abnormal bone marrow cavity morphology | 1.83e-03 | 27 | 33 | 2 | MP:0000065 | |
| MousePheno | abnormal heart ventricle wall thickness | 1.91e-03 | 227 | 33 | 4 | MP:0020135 | |
| MousePheno | abnormal ear position | 1.97e-03 | 28 | 33 | 2 | MP:0000023 | |
| MousePheno | abnormal supraoccipital bone morphology | 2.11e-03 | 29 | 33 | 2 | MP:0000078 | |
| MousePheno | abnormal brain ventricular system morphology | 2.12e-03 | 393 | 33 | 5 | MP:0002200 | |
| MousePheno | increased adiponectin level | 2.26e-03 | 30 | 33 | 2 | MP:0004892 | |
| MousePheno | abnormal cardiovascular development | 2.29e-03 | 802 | 33 | 7 | MP:0002925 | |
| MousePheno | abnormal hematopoietic stem cell morphology | 2.29e-03 | 112 | 33 | 3 | MP:0004808 | |
| Domain | Neuroggenic_mastermind-like_N | 1.27e-05 | 3 | 39 | 2 | IPR019082 | |
| Domain | MamL-1 | 1.27e-05 | 3 | 39 | 2 | SM01275 | |
| Domain | MamL-1 | 1.27e-05 | 3 | 39 | 2 | PF09596 | |
| Domain | ARM-like | 1.89e-05 | 270 | 39 | 6 | IPR011989 | |
| Domain | HSA | 2.54e-05 | 4 | 39 | 2 | SM00573 | |
| Domain | HSA | 2.54e-05 | 4 | 39 | 2 | PS51204 | |
| Domain | HSA_dom | 2.54e-05 | 4 | 39 | 2 | IPR014012 | |
| Domain | HSA | 2.54e-05 | 4 | 39 | 2 | PF07529 | |
| Domain | Nuc_rcpt_coact | 6.34e-05 | 6 | 39 | 2 | IPR009110 | |
| Domain | Homeodomain-like | 6.04e-04 | 332 | 39 | 5 | IPR009057 | |
| Domain | Pentatricopeptide_repeat | 1.05e-03 | 23 | 39 | 2 | IPR002885 | |
| Domain | - | 1.15e-03 | 222 | 39 | 4 | 1.25.10.10 | |
| Domain | Bromodomain_CS | 1.34e-03 | 26 | 39 | 2 | IPR018359 | |
| Domain | - | 1.44e-03 | 27 | 39 | 2 | 1.10.260.40 | |
| Domain | Lambda_DNA-bd_dom | 1.66e-03 | 29 | 39 | 2 | IPR010982 | |
| Domain | SNF2_N | 2.03e-03 | 32 | 39 | 2 | PF00176 | |
| Domain | SNF2_N | 2.03e-03 | 32 | 39 | 2 | IPR000330 | |
| Domain | BROMODOMAIN_1 | 2.70e-03 | 37 | 39 | 2 | PS00633 | |
| Domain | - | 2.80e-03 | 283 | 39 | 4 | 1.10.10.60 | |
| Domain | MYB_LIKE | 2.85e-03 | 38 | 39 | 2 | PS50090 | |
| Domain | Bromodomain | 2.85e-03 | 38 | 39 | 2 | PF00439 | |
| Domain | BROMODOMAIN_2 | 3.31e-03 | 41 | 39 | 2 | PS50014 | |
| Domain | BROMO | 3.47e-03 | 42 | 39 | 2 | SM00297 | |
| Domain | Bromodomain | 3.47e-03 | 42 | 39 | 2 | IPR001487 | |
| Domain | - | 3.47e-03 | 42 | 39 | 2 | 1.20.920.10 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION | 4.40e-08 | 84 | 34 | 6 | M1008 | |
| Pathway | KEGG_NOTCH_SIGNALING_PATHWAY | 8.57e-08 | 47 | 34 | 5 | M7946 | |
| Pathway | PID_HES_HEY_PATHWAY | 9.55e-08 | 48 | 34 | 5 | M288 | |
| Pathway | REACTOME_RNA_POLYMERASE_II_TRANSCRIPTION | MED15 SMARCA2 NCOR2 ZFHX3 ARID1B KMT2D MAML2 RUNX2 CREBBP MAML3 AR MED12 PHC1 HTT TBP | 2.21e-07 | 1387 | 34 | 15 | M734 |
| Pathway | REACTOME_ADIPOGENESIS | 2.22e-07 | 110 | 34 | 6 | M48259 | |
| Pathway | BIOCARTA_RARRXR_PATHWAY | 2.55e-07 | 6 | 34 | 3 | MM1447 | |
| Pathway | REACTOME_REGULATION_OF_LIPID_METABOLISM_BY_PPARALPHA | 3.36e-07 | 118 | 34 | 6 | M27316 | |
| Pathway | WP_MECHANISMS_ASSOCIATED_WITH_PLURIPOTENCY | 4.41e-07 | 301 | 34 | 8 | MM15983 | |
| Pathway | WP_PATHWAYS_AFFECTED_IN_ADENOID_CYSTIC_CARCINOMA | 4.47e-07 | 65 | 34 | 5 | M39682 | |
| Pathway | REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY | 5.54e-07 | 28 | 34 | 4 | M6177 | |
| Pathway | WP_ANDROGEN_RECEPTOR_SIGNALING | 2.41e-06 | 91 | 34 | 5 | M39700 | |
| Pathway | WP_NOTCH_SIGNALING_WP268 | 3.92e-06 | 45 | 34 | 4 | M39571 | |
| Pathway | WP_NOTCH_SIGNALING_PATHWAY | 4.28e-06 | 46 | 34 | 4 | MM15971 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 4.58e-06 | 14 | 34 | 3 | M27808 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 5.09e-06 | 48 | 34 | 4 | M611 | |
| Pathway | REACTOME_REGULATION_OF_GENE_EXPRESSION_IN_LATE_STAGE_BRANCHING_MORPHOGENESIS_PANCREATIC_BUD_PRECURSOR_CELLS | 7.03e-06 | 16 | 34 | 3 | M27121 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1_PEST_DOMAIN_MUTANTS_IN_CANCER | 1.09e-05 | 58 | 34 | 4 | M29616 | |
| Pathway | WP_NOTCH_SIGNALING_WP61 | 1.34e-05 | 61 | 34 | 4 | M39540 | |
| Pathway | REACTOME_NOTCH4_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.42e-05 | 20 | 34 | 3 | M27881 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX1 | 1.92e-05 | 237 | 34 | 6 | M27786 | |
| Pathway | REACTOME_NOTCH_HLH_TRANSCRIPTION_PATHWAY | 2.20e-05 | 23 | 34 | 3 | MM14954 | |
| Pathway | REACTOME_NOTCH3_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 2.84e-05 | 25 | 34 | 3 | M27880 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 2.88e-05 | 74 | 34 | 4 | M616 | |
| Pathway | BIOCARTA_CARM_ER_PATHWAY | 3.21e-05 | 26 | 34 | 3 | M2499 | |
| Pathway | REACTOME_CHROMATIN_MODIFYING_ENZYMES | 4.17e-05 | 272 | 34 | 6 | M29619 | |
| Pathway | WP_DELTANOTCH_SIGNALING_PATHWAY | 4.32e-05 | 82 | 34 | 4 | MM15922 | |
| Pathway | PID_SMAD2_3NUCLEAR_PATHWAY | 4.32e-05 | 82 | 34 | 4 | M2 | |
| Pathway | WP_KLEEFSTRA_SYNDROME | 4.49e-05 | 29 | 34 | 3 | M48076 | |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 4.98e-05 | 30 | 34 | 3 | M207 | |
| Pathway | REACTOME_GENERIC_TRANSCRIPTION_PATHWAY | 6.17e-05 | 768 | 34 | 9 | MM14851 | |
| Pathway | REACTOME_DEVELOPMENTAL_BIOLOGY | MED15 SMARCA2 NCOA3 NCOR2 POU3F2 NCOA6 ARID1B KMT2D MAML2 CREBBP MAML3 MED12 | 7.51e-05 | 1432 | 34 | 12 | M509 |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 8.01e-05 | 96 | 34 | 4 | M27784 | |
| Pathway | REACTOME_SUMOYLATION | 8.34e-05 | 189 | 34 | 5 | M27214 | |
| Pathway | REACTOME_RUNX1_INTERACTS_WITH_CO_FACTORS_WHOSE_PRECISE_EFFECT_ON_RUNX1_TARGETS_IS_NOT_KNOWN | 9.42e-05 | 37 | 34 | 3 | M27797 | |
| Pathway | REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_DIFFERENTIATION_OF_MYELOID_CELLS | 1.18e-04 | 7 | 34 | 2 | M27799 | |
| Pathway | REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT | 1.18e-04 | 7 | 34 | 2 | MM15533 | |
| Pathway | BIOCARTA_RARRXR_PATHWAY | 1.18e-04 | 7 | 34 | 2 | M6907 | |
| Pathway | REACTOME_REGULATION_OF_BETA_CELL_DEVELOPMENT | 1.38e-04 | 42 | 34 | 3 | M17541 | |
| Pathway | PID_HNF3A_PATHWAY | 1.59e-04 | 44 | 34 | 3 | M285 | |
| Pathway | REACTOME_SUMOYLATION_OF_TRANSCRIPTION_COFACTORS | 1.59e-04 | 44 | 34 | 3 | M27295 | |
| Pathway | REACTOME_ACTIVATION_OF_ANTERIOR_HOX_GENES_IN_HINDBRAIN_DEVELOPMENT_DURING_EARLY_EMBRYOGENESIS | 2.03e-04 | 122 | 34 | 4 | M29689 | |
| Pathway | WP_RETT_SYNDROME | 2.06e-04 | 48 | 34 | 3 | M39759 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH3 | 2.19e-04 | 49 | 34 | 3 | M618 | |
| Pathway | REACTOME_RUNX3_REGULATES_NOTCH_SIGNALING | 2.51e-04 | 10 | 34 | 2 | MM15535 | |
| Pathway | PID_AR_TF_PATHWAY | 2.77e-04 | 53 | 34 | 3 | M151 | |
| Pathway | REACTOME_MITF_M_REGULATED_MELANOCYTE_DEVELOPMENT | 3.16e-04 | 137 | 34 | 4 | M48232 | |
| Pathway | REACTOME_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION | 3.31e-04 | 254 | 34 | 5 | M27131 | |
| Pathway | REACTOME_NOTCH2_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 3.67e-04 | 12 | 34 | 2 | M27159 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00380 | 3.67e-04 | 12 | 34 | 2 | M47532 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00381 | 3.67e-04 | 12 | 34 | 2 | M47533 | |
| Pathway | REACTOME_CYTOPROTECTION_BY_HMOX1 | 3.99e-04 | 60 | 34 | 3 | M41830 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HPV_E6_TO_NOTCH_SIGNALING_PATHWAY_N00382 | 4.33e-04 | 13 | 34 | 2 | M47534 | |
| Pathway | PID_RB_1PATHWAY | 5.06e-04 | 65 | 34 | 3 | M279 | |
| Pathway | REACTOME_GENE_EXPRESSION_TRANSCRIPTION | 5.35e-04 | 1022 | 34 | 9 | MM15436 | |
| Pathway | WP_RUBINSTEINTAYBI_SYNDROME_1 | 5.81e-04 | 15 | 34 | 2 | M48323 | |
| Pathway | REACTOME_FORMATION_OF_PARAXIAL_MESODERM | 6.02e-04 | 69 | 34 | 3 | M46439 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_RUNX3 | 7.99e-04 | 76 | 34 | 3 | MM15520 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 8.43e-04 | 18 | 34 | 2 | MM14775 | |
| Pathway | REACTOME_RORA_ACTIVATES_GENE_EXPRESSION | 8.43e-04 | 18 | 34 | 2 | M26942 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH4 | 9.97e-04 | 82 | 34 | 3 | M594 | |
| Pathway | PID_CMYB_PATHWAY | 1.07e-03 | 84 | 34 | 3 | M195 | |
| Pathway | BIOCARTA_VDR_PATHWAY | 1.27e-03 | 22 | 34 | 2 | MM1370 | |
| Pathway | REACTOME_RUNX2_REGULATES_OSTEOBLAST_DIFFERENTIATION | 1.51e-03 | 24 | 34 | 2 | M27803 | |
| Pathway | REACTOME_MITF_M_DEPENDENT_GENE_EXPRESSION | 1.52e-03 | 95 | 34 | 3 | M48268 | |
| Pathway | REACTOME_RSV_HOST_INTERACTIONS | 1.67e-03 | 98 | 34 | 3 | M48247 | |
| Pathway | KEGG_MEDICUS_VARIANT_MLL_AF4_FUSION_TO_TRANSCRIPTIONAL_ACTIVATION | 1.77e-03 | 26 | 34 | 2 | M47439 | |
| Pathway | WP_CANONICAL_AND_NONCANONICAL_NOTCH_SIGNALING | 1.91e-03 | 27 | 34 | 2 | M39545 | |
| Pathway | REACTOME_BMAL1_CLOCK_NPAS2_ACTIVATES_CIRCADIAN_GENE_EXPRESSION | 1.91e-03 | 27 | 34 | 2 | M26943 | |
| Pathway | REACTOME_RUNX2_REGULATES_BONE_DEVELOPMENT | 2.51e-03 | 31 | 34 | 2 | M27805 | |
| Pathway | REACTOME_REGULATION_OF_MECP2_EXPRESSION_AND_ACTIVITY | 2.68e-03 | 32 | 34 | 2 | M27900 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 2.78e-03 | 246 | 34 | 4 | M10189 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH2 | 2.84e-03 | 33 | 34 | 2 | M604 | |
| Pathway | REACTOME_PRE_NOTCH_EXPRESSION_AND_PROCESSING | 2.90e-03 | 119 | 34 | 3 | M607 | |
| Pathway | REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY | 2.97e-03 | 120 | 34 | 3 | M48233 | |
| Pathway | KEGG_MEDICUS_REFERENCE_ADRB3_UCP1_SIGNALING_PATHWAY | 3.20e-03 | 35 | 34 | 2 | M47969 | |
| Pathway | REACTOME_GASTRULATION | 3.64e-03 | 129 | 34 | 3 | M46433 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH | 3.96e-03 | 39 | 34 | 2 | MM14604 | |
| Pathway | REACTOME_REGULATION_OF_MITF_M_DEPENDENT_GENES_INVOLVED_IN_PIGMENTATION | 4.58e-03 | 42 | 34 | 2 | M48237 | |
| Pathway | REACTOME_FORMATION_OF_WDR5_CONTAINING_HISTONE_MODIFYING_COMPLEXES | 4.58e-03 | 42 | 34 | 2 | M48018 | |
| Pathway | REACTOME_ACTIVATION_OF_GENE_EXPRESSION_BY_SREBF_SREBP | 4.58e-03 | 42 | 34 | 2 | M27172 | |
| Pathway | REACTOME_SIGNALING_BY_NUCLEAR_RECEPTORS | 5.38e-03 | 296 | 34 | 4 | M27869 | |
| Pathway | REACTOME_ESTROGEN_DEPENDENT_GENE_EXPRESSION | 5.45e-03 | 149 | 34 | 3 | M27888 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 5.94e-03 | 48 | 34 | 2 | MM14987 | |
| Pathway | WP_MIRNA_REGULATION_OF_PROSTATE_CANCER_SIGNALING | 6.19e-03 | 49 | 34 | 2 | M39683 | |
| Pathway | REACTOME_HEME_SIGNALING | 6.19e-03 | 49 | 34 | 2 | M41832 | |
| Pathway | WP_SUDDEN_INFANT_DEATH_SYNDROME_SIDS_SUSCEPTIBILITY_PATHWAYS | 6.52e-03 | 159 | 34 | 3 | M39373 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_AND_POST_TRANSLATIONAL_REGULATION_OF_MITF_M_EXPRESSION_AND_ACTIVITY | 6.69e-03 | 51 | 34 | 2 | M48267 | |
| Pathway | BIOCARTA_PPARA_PATHWAY | 6.94e-03 | 52 | 34 | 2 | M2404 | |
| Pathway | WP_TGFBETA_SIGNALING_PATHWAY | 7.20e-03 | 53 | 34 | 2 | MM15880 | |
| Pathway | REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY | 7.20e-03 | 53 | 34 | 2 | M8276 | |
| Pathway | REACTOME_SUMOYLATION | 7.71e-03 | 169 | 34 | 3 | MM14919 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING | 7.74e-03 | 55 | 34 | 2 | M39351 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_ACTIVATION_OF_MITOCHONDRIAL_BIOGENESIS | 7.74e-03 | 55 | 34 | 2 | M27145 | |
| Pathway | REACTOME_REGULATION_OF_CHOLESTEROL_BIOSYNTHESIS_BY_SREBP_SREBF | 7.74e-03 | 55 | 34 | 2 | M27001 | |
| Pathway | WP_OVERLAP_BETWEEN_SIGNAL_TRANSDUCTION_PATHWAYS_CONTRIBUTING_TO_LMNA_LAMINOPATHIES | 8.29e-03 | 57 | 34 | 2 | M39877 | |
| Pathway | REACTOME_METABOLISM_OF_LIPIDS | 8.70e-03 | 757 | 34 | 6 | M27451 | |
| Pathway | WP_TGFBETA_RECEPTOR_SIGNALING_IN_SKELETAL_DYSPLASIAS | 8.86e-03 | 59 | 34 | 2 | M39886 | |
| Pathway | PID_NOTCH_PATHWAY | 8.86e-03 | 59 | 34 | 2 | M17 | |
| Pathway | KEGG_HUNTINGTONS_DISEASE | 9.44e-03 | 182 | 34 | 3 | M13486 | |
| Pathway | PID_AR_PATHWAY | 9.45e-03 | 61 | 34 | 2 | M58 | |
| Pubmed | MED15 MAGI1 NCOA3 ZNF384 NCOR2 KMT2D EP400 FOXP2 NUMBL ATXN2 MAML3 MED12 | 1.15e-30 | 23 | 40 | 12 | 9225980 | |
| Pubmed | Interaction network of human early embryonic transcription factors. | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D ATN1 SATB1 EP400 FOXP2 ATXN1 CREBBP MED12 | 2.72e-20 | 351 | 40 | 15 | 38297188 |
| Pubmed | MED15 SMARCA2 NCOA3 NCOA6 ARID1B KMT2D ATN1 EP400 ATXN1 CREBBP AR MED12 | 1.58e-16 | 268 | 40 | 12 | 33640491 | |
| Pubmed | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 IRF2BPL ZFHX3 ARID1B KMT2D ATN1 SATB1 EP400 FOXP2 VEZF1 ATXN1 ATXN2 CREBBP TBP THAP11 | 2.35e-16 | 1429 | 40 | 19 | 35140242 | |
| Pubmed | 3.70e-16 | 23 | 40 | 7 | 26002199 | ||
| Pubmed | 4.13e-16 | 83 | 40 | 9 | 28794006 | ||
| Pubmed | MED15 SMARCA2 NCOA3 ZNF384 NCOR2 NCOA6 ARID1B KMT2D RUNX2 EP400 VEZF1 ATXN2 CREBBP MED12 THAP11 | 5.76e-13 | 1103 | 40 | 15 | 34189442 | |
| Pubmed | Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation. | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D ATN1 ATXN2 CREBBP MAML3 | 2.94e-12 | 457 | 40 | 11 | 32344865 |
| Pubmed | TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation. | 3.17e-12 | 220 | 40 | 9 | 35785414 | |
| Pubmed | 3.80e-12 | 78 | 40 | 7 | 28611094 | ||
| Pubmed | Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. | 5.83e-12 | 40 | 40 | 6 | 34585037 | |
| Pubmed | 2.25e-11 | 6 | 40 | 4 | 8896557 | ||
| Pubmed | The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1). | 5.23e-11 | 7 | 40 | 4 | 10860780 | |
| Pubmed | 5.23e-11 | 7 | 40 | 4 | 14756671 | ||
| Pubmed | 5.23e-11 | 7 | 40 | 4 | 16858508 | ||
| Pubmed | 5.23e-11 | 7 | 40 | 4 | 11121205 | ||
| Pubmed | A census of human transcription factors: function, expression and evolution. | NCOA3 ZNF384 POU3F2 ZFHX3 KMT2D USF3 RUNX2 SATB1 FOXP2 NFAT5 AR THAP11 | 2.66e-10 | 908 | 40 | 12 | 19274049 |
| Pubmed | The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study. | 3.13e-10 | 10 | 40 | 4 | 19259763 | |
| Pubmed | Screening for premutation in the FMR1 gene in male patients suspected of spinocerebellar ataxia. | 3.13e-10 | 10 | 40 | 4 | 19235102 | |
| Pubmed | 5.49e-10 | 157 | 40 | 7 | 30186101 | ||
| Pubmed | Identification and functional characterization of transcriptional activators in human cells. | 6.15e-10 | 398 | 40 | 9 | 35016035 | |
| Pubmed | An Oct4-centered protein interaction network in embryonic stem cells. | 8.46e-10 | 167 | 40 | 7 | 20362541 | |
| Pubmed | 1.04e-09 | 92 | 40 | 6 | 20301317 | ||
| Pubmed | SMARCA2 NCOA3 ZFHX3 RUNX2 SATB1 FOXP2 VEZF1 NFAT5 ATXN1 PHC1 TBP | 1.24e-09 | 808 | 40 | 11 | 20412781 | |
| Pubmed | 1.41e-09 | 3 | 40 | 3 | 15225551 | ||
| Pubmed | dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1. | 1.41e-09 | 3 | 40 | 3 | 18166084 | |
| Pubmed | 2.03e-09 | 15 | 40 | 4 | 9267036 | ||
| Pubmed | 3.53e-09 | 17 | 40 | 4 | 19183483 | ||
| Pubmed | 5.63e-09 | 4 | 40 | 3 | 11807410 | ||
| Pubmed | 5.63e-09 | 4 | 40 | 3 | 18651325 | ||
| Pubmed | 5.63e-09 | 4 | 40 | 3 | 17868456 | ||
| Pubmed | Expanded CAG Repeats in ATXN1, ATXN2, ATXN3, and HTT in the 1000 Genomes Project. | 5.63e-09 | 4 | 40 | 3 | 33159825 | |
| Pubmed | 5.63e-09 | 4 | 40 | 3 | 10332029 | ||
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | SMARCA2 MAGI1 NCOR2 ZFHX3 USF3 NUMBL NFAT5 ATXN1 ATXN2 CREBBP MAML3 AR HTT | 6.29e-09 | 1489 | 40 | 13 | 28611215 |
| Pubmed | 7.17e-09 | 20 | 40 | 4 | 11877444 | ||
| Pubmed | 8.85e-09 | 21 | 40 | 4 | 19596656 | ||
| Pubmed | 1.22e-08 | 65 | 40 | 5 | 22496869 | ||
| Pubmed | 1.32e-08 | 66 | 40 | 5 | 23275444 | ||
| Pubmed | 1.41e-08 | 5 | 40 | 3 | 18182848 | ||
| Pubmed | Genetic interaction mapping in mammalian cells using CRISPR interference. | 1.65e-08 | 69 | 40 | 5 | 28481362 | |
| Pubmed | Proteome-scale mapping of binding sites in the unstructured regions of the human proteome. | 2.78e-08 | 430 | 40 | 8 | 35044719 | |
| Pubmed | 2.81e-08 | 6 | 40 | 3 | 23652004 | ||
| Pubmed | 2.81e-08 | 6 | 40 | 3 | 16389595 | ||
| Pubmed | 2.81e-08 | 6 | 40 | 3 | 28445460 | ||
| Pubmed | 3.01e-08 | 28 | 40 | 4 | 24880616 | ||
| Pubmed | SMARCA2 NCOR2 ZFHX3 ARID1B ATN1 EP400 FOXP2 ATXN1 PHLDA1 CREBBP TBP | 3.48e-08 | 1116 | 40 | 11 | 31753913 | |
| Pubmed | 3.66e-08 | 638 | 40 | 9 | 31182584 | ||
| Pubmed | Novel triplet repeat containing genes in human brain: cloning, expression, and length polymorphisms. | 4.92e-08 | 7 | 40 | 3 | 8325628 | |
| Pubmed | 7.86e-08 | 8 | 40 | 3 | 17475621 | ||
| Pubmed | 8.99e-08 | 709 | 40 | 9 | 22988430 | ||
| Pubmed | 1.18e-07 | 9 | 40 | 3 | 19176441 | ||
| Pubmed | 1.18e-07 | 9 | 40 | 3 | 9535906 | ||
| Pubmed | 1.51e-07 | 107 | 40 | 5 | 11347906 | ||
| Pubmed | Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. | 1.68e-07 | 10 | 40 | 3 | 16751102 | |
| Pubmed | 1.68e-07 | 10 | 40 | 3 | 18087039 | ||
| Pubmed | 1.81e-07 | 549 | 40 | 8 | 38280479 | ||
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | 1.89e-07 | 774 | 40 | 9 | 15302935 | |
| Pubmed | 3.08e-07 | 12 | 40 | 3 | 11158331 | ||
| Pubmed | 4.00e-07 | 13 | 40 | 3 | 11266503 | ||
| Pubmed | 4.56e-07 | 418 | 40 | 7 | 34709266 | ||
| Pubmed | Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome. | 5.08e-07 | 14 | 40 | 3 | 36289231 | |
| Pubmed | 5.08e-07 | 14 | 40 | 3 | 12482968 | ||
| Pubmed | 6.35e-07 | 15 | 40 | 3 | 23785148 | ||
| Pubmed | 6.35e-07 | 15 | 40 | 3 | 10567404 | ||
| Pubmed | 7.81e-07 | 453 | 40 | 7 | 29656893 | ||
| Pubmed | 8.68e-07 | 152 | 40 | 5 | 38360978 | ||
| Pubmed | 9.48e-07 | 17 | 40 | 3 | 15148151 | ||
| Pubmed | 9.65e-07 | 65 | 40 | 4 | 26655900 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 34953044 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 19223455 | ||
| Pubmed | Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. | 1.29e-06 | 2 | 40 | 2 | 16456924 | |
| Pubmed | Patterns of CAG repeat interruptions in SCA1 and SCA2 genes in relation to repeat instability. | 1.29e-06 | 2 | 40 | 2 | 15300851 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 20140226 | ||
| Pubmed | A common motif targets huntingtin and the androgen receptor to the proteasome. | 1.29e-06 | 2 | 40 | 2 | 18586675 | |
| Pubmed | Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. | 1.29e-06 | 2 | 40 | 2 | 23197749 | |
| Pubmed | Role of CBP and SATB-1 in aging, dietary restriction, and insulin-like signaling. | 1.29e-06 | 2 | 40 | 2 | 19924292 | |
| Pubmed | Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. | 1.29e-06 | 2 | 40 | 2 | 15994095 | |
| Pubmed | Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. | 1.29e-06 | 2 | 40 | 2 | 16766198 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 20541699 | ||
| Pubmed | CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. | 1.29e-06 | 2 | 40 | 2 | 9822653 | |
| Pubmed | Early alteration of epigenetic-related transcription in Huntington's disease mouse models. | 1.29e-06 | 2 | 40 | 2 | 29967375 | |
| Pubmed | A ketogenic diet rescues hippocampal memory defects in a mouse model of Kabuki syndrome. | 1.29e-06 | 2 | 40 | 2 | 27999180 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 16921507 | ||
| Pubmed | Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. | 1.29e-06 | 2 | 40 | 2 | 12441355 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 17627815 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 11927493 | ||
| Pubmed | Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA. | 1.29e-06 | 2 | 40 | 2 | 11442350 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 28675294 | ||
| Pubmed | Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator. | 1.29e-06 | 2 | 40 | 2 | 10965917 | |
| Pubmed | Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. | 1.29e-06 | 2 | 40 | 2 | 11747336 | |
| Pubmed | Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor. | 1.29e-06 | 2 | 40 | 2 | 20086010 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 10410676 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 32408088 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 11264541 | ||
| Pubmed | Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. | 1.29e-06 | 2 | 40 | 2 | 21632823 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 36029989 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 22116937 | ||
| Pubmed | The amino terminus of the human AR is target for corepressor action and antihormone agonism. | 1.29e-06 | 2 | 40 | 2 | 11923464 | |
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 8758910 | ||
| Pubmed | 1.29e-06 | 2 | 40 | 2 | 27392123 | ||
| Interaction | EGR2 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D ATN1 EP400 FOXP2 ATXN1 CREBBP | 3.02e-16 | 171 | 39 | 12 | int:EGR2 |
| Interaction | CRX interactions | MED15 SMARCA2 NCOA3 NCOR2 ZFHX3 ARID1B KMT2D ATN1 EP400 FOXP2 ATXN1 CREBBP MED12 | 9.04e-16 | 254 | 39 | 13 | int:CRX |
| Interaction | FEV interactions | NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D SATB1 EP400 FOXP2 VEZF1 ATXN1 CREBBP | 2.42e-15 | 203 | 39 | 12 | int:FEV |
| Interaction | TBXT interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D ATN1 SATB1 ATXN1 CREBBP | 1.49e-14 | 116 | 39 | 10 | int:TBXT |
| Interaction | PAX9 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D ATN1 SATB1 ATXN1 | 4.76e-14 | 130 | 39 | 10 | int:PAX9 |
| Interaction | GSC interactions | 6.49e-14 | 87 | 39 | 9 | int:GSC | |
| Interaction | KLF5 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D EP400 ATXN1 CREBBP AR TBP | 6.94e-14 | 195 | 39 | 11 | int:KLF5 |
| Interaction | PAX6 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D SATB1 EP400 ATXN1 CREBBP AR TBP | 1.00e-13 | 366 | 39 | 13 | int:PAX6 |
| Interaction | SOX9 interactions | 1.78e-13 | 97 | 39 | 9 | int:SOX9 | |
| Interaction | ETV4 interactions | 7.02e-13 | 69 | 39 | 8 | int:ETV4 | |
| Interaction | AR interactions | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 IRF2BPL ZFHX3 ARID1B KMT2D RUNX2 ATN1 EP400 ATXN1 CREBBP AR MED12 TBP | 9.35e-13 | 992 | 39 | 17 | int:AR |
| Interaction | ETS1 interactions | 1.37e-12 | 121 | 39 | 9 | int:ETS1 | |
| Interaction | PAX7 interactions | 1.71e-12 | 124 | 39 | 9 | int:PAX7 | |
| Interaction | HNF1B interactions | SMARCA2 NCOA3 NCOR2 ZFHX3 ARID1B KMT2D SATB1 EP400 ATXN1 CREBBP | 2.19e-12 | 190 | 39 | 10 | int:HNF1B |
| Interaction | CREBBP interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D MAML2 RUNX2 ATXN1 PHLDA1 CREBBP AR HTT TBP | 2.75e-12 | 599 | 39 | 14 | int:CREBBP |
| Interaction | HNF4A interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D EP400 ATXN1 CREBBP AR TBP | 2.99e-12 | 275 | 39 | 11 | int:HNF4A |
| Interaction | GATA2 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D SATB1 ATXN1 CREBBP | 3.48e-12 | 199 | 39 | 10 | int:GATA2 |
| Interaction | SP7 interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D ATN1 SATB1 EP400 ATXN1 CREBBP | 8.85e-12 | 304 | 39 | 11 | int:SP7 |
| Interaction | CTBP1 interactions | MED15 NCOR2 MAML2 SATB1 EP400 FOXP2 ATXN1 CREBBP AR HTT TBP THAP11 | 9.10e-12 | 406 | 39 | 12 | int:CTBP1 |
| Interaction | FOS interactions | SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D RUNX2 EP400 NFAT5 CREBBP TBP | 1.17e-11 | 312 | 39 | 11 | int:FOS |
| Interaction | TLX1 interactions | 3.87e-11 | 175 | 39 | 9 | int:TLX1 | |
| Interaction | TBR1 interactions | 4.05e-11 | 113 | 39 | 8 | int:TBR1 | |
| Interaction | TEAD1 interactions | 4.07e-11 | 176 | 39 | 9 | int:TEAD1 | |
| Interaction | NFIA interactions | 7.35e-11 | 188 | 39 | 9 | int:NFIA | |
| Interaction | TLE3 interactions | MED15 NCOA3 NCOR2 ZFHX3 ARID1B KMT2D ATN1 VEZF1 ATXN1 CREBBP AR | 8.65e-11 | 376 | 39 | 11 | int:TLE3 |
| Interaction | IRF4 interactions | 2.55e-10 | 85 | 39 | 7 | int:IRF4 | |
| Interaction | NFIB interactions | 2.55e-10 | 142 | 39 | 8 | int:NFIB | |
| Interaction | NCOA6 interactions | 3.01e-10 | 145 | 39 | 8 | int:NCOA6 | |
| Interaction | NUP35 interactions | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D ATN1 ATXN2 CREBBP MAML3 | 3.10e-10 | 424 | 39 | 11 | int:NUP35 |
| Interaction | ERG interactions | 3.36e-10 | 223 | 39 | 9 | int:ERG | |
| Interaction | CEBPA interactions | MED15 SMARCA2 NCOA3 ZNF384 NCOR2 NCOA6 ARID1B KMT2D RUNX2 EP400 VEZF1 ATXN2 CREBBP AR MED12 THAP11 | 3.99e-10 | 1245 | 39 | 16 | int:CEBPA |
| Interaction | FOXI1 interactions | 4.47e-10 | 92 | 39 | 7 | int:FOXI1 | |
| Interaction | RELA interactions | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ZFHX3 KMT2D ATXN1 CREBBP AR TBP | 1.28e-09 | 485 | 39 | 11 | int:RELA |
| Interaction | PAX8 interactions | 1.69e-09 | 111 | 39 | 7 | int:PAX8 | |
| Interaction | LHX2 interactions | 1.92e-09 | 183 | 39 | 8 | int:LHX2 | |
| Interaction | TLX3 interactions | 3.50e-09 | 291 | 39 | 9 | int:TLX3 | |
| Interaction | GCM1 interactions | 3.52e-09 | 68 | 39 | 6 | int:GCM1 | |
| Interaction | E2F1 interactions | 3.87e-09 | 200 | 39 | 8 | int:E2F1 | |
| Interaction | NFIC interactions | 5.67e-09 | 210 | 39 | 8 | int:NFIC | |
| Interaction | NFIX interactions | 1.04e-08 | 227 | 39 | 8 | int:NFIX | |
| Interaction | SOX7 interactions | 1.10e-08 | 82 | 39 | 6 | int:SOX7 | |
| Interaction | JUN interactions | 1.50e-08 | 470 | 39 | 10 | int:JUN | |
| Interaction | SOX10 interactions | 2.22e-08 | 92 | 39 | 6 | int:SOX10 | |
| Interaction | TBP interactions | 2.43e-08 | 253 | 39 | 8 | int:TBP | |
| Interaction | RBPJ interactions | 2.50e-08 | 254 | 39 | 8 | int:RBPJ | |
| Interaction | FOXP1 interactions | 2.66e-08 | 256 | 39 | 8 | int:FOXP1 | |
| Interaction | SOX17 interactions | 2.69e-08 | 95 | 39 | 6 | int:SOX17 | |
| Interaction | PIAS3 interactions | 2.69e-08 | 95 | 39 | 6 | int:PIAS3 | |
| Interaction | FHL2 interactions | 5.02e-08 | 396 | 39 | 9 | int:FHL2 | |
| Interaction | LHX3 interactions | 5.88e-08 | 185 | 39 | 7 | int:LHX3 | |
| Interaction | GATA3 interactions | 6.33e-08 | 187 | 39 | 7 | int:GATA3 | |
| Interaction | SUMO1 interactions | 6.44e-08 | 287 | 39 | 8 | int:SUMO1 | |
| Interaction | HCFC1 interactions | 7.55e-08 | 293 | 39 | 8 | int:HCFC1 | |
| Interaction | MYOD1 interactions | 8.15e-08 | 194 | 39 | 7 | int:MYOD1 | |
| Interaction | HDAC1 interactions | SMARCA2 NCOR2 ZFHX3 KMT2D RUNX2 SATB1 EP400 ATXN1 CREBBP AR MED12 TBP THAP11 | 8.32e-08 | 1108 | 39 | 13 | int:HDAC1 |
| Interaction | KDM1A interactions | SMARCA2 NCOA3 NCOR2 ZFHX3 KMT2D SATB1 EP400 ATXN1 AR MED12 PHC1 HTT | 1.22e-07 | 941 | 39 | 12 | int:KDM1A |
| Interaction | KMT2A interactions | 1.28e-07 | 314 | 39 | 8 | int:KMT2A | |
| Interaction | RNF4 interactions | ZNF384 NCOR2 ARID1B ATN1 VEZF1 BMP2K ATXN1 PHLDA1 ATXN2 AR MED12 PHC1 HTT TBP | 1.84e-07 | 1412 | 39 | 14 | int:RNF4 |
| Interaction | MED15 interactions | 1.84e-07 | 131 | 39 | 6 | int:MED15 | |
| Interaction | NCOA3 interactions | 2.17e-07 | 224 | 39 | 7 | int:NCOA3 | |
| Interaction | KLF3 interactions | 2.45e-07 | 228 | 39 | 7 | int:KLF3 | |
| Interaction | NCOA1 interactions | 3.49e-07 | 146 | 39 | 6 | int:NCOA1 | |
| Interaction | SREBF1 interactions | 4.10e-07 | 150 | 39 | 6 | int:SREBF1 | |
| Interaction | KAT2B interactions | 5.35e-07 | 256 | 39 | 7 | int:KAT2B | |
| Interaction | SIN3A interactions | 5.48e-07 | 380 | 39 | 8 | int:SIN3A | |
| Interaction | KLF4 interactions | 5.99e-07 | 160 | 39 | 6 | int:KLF4 | |
| Interaction | PAX2 interactions | 6.09e-07 | 85 | 39 | 5 | int:PAX2 | |
| Interaction | YAP1 interactions | MED15 SMARCA2 POU3F2 NCOA6 ARID1B KMT2D RUNX2 ATN1 NFAT5 CREBBP AR MED12 | 6.22e-07 | 1095 | 39 | 12 | int:YAP1 |
| Interaction | SOX5 interactions | 6.44e-07 | 162 | 39 | 6 | int:SOX5 | |
| Interaction | MED23 interactions | 6.91e-07 | 266 | 39 | 7 | int:MED23 | |
| Interaction | LHX4 interactions | 7.43e-07 | 166 | 39 | 6 | int:LHX4 | |
| Interaction | EPAS1 interactions | 9.46e-07 | 173 | 39 | 6 | int:EPAS1 | |
| Interaction | KLF15 interactions | 1.23e-06 | 290 | 39 | 7 | int:KLF15 | |
| Interaction | EP300 interactions | SMARCA2 NCOA3 NCOR2 POU3F2 NCOA6 KMT2D MAML2 RUNX2 SATB1 MN1 CREBBP AR TBP | 1.23e-06 | 1401 | 39 | 13 | int:EP300 |
| Interaction | ALG13 interactions | 1.31e-06 | 183 | 39 | 6 | int:ALG13 | |
| Interaction | NR3C1 interactions | MED15 SMARCA2 NCOA3 NCOR2 NCOA6 ARID1B KMT2D CREBBP MAML3 AR TBP | 1.53e-06 | 974 | 39 | 11 | int:NR3C1 |
| Interaction | LHX1 interactions | 1.59e-06 | 103 | 39 | 5 | int:LHX1 | |
| Interaction | NFYA interactions | 1.74e-06 | 105 | 39 | 5 | int:NFYA | |
| Interaction | PPARG interactions | 1.80e-06 | 307 | 39 | 7 | int:PPARG | |
| Interaction | SMAD3 interactions | 1.85e-06 | 447 | 39 | 8 | int:SMAD3 | |
| Interaction | NR1I3 interactions | 2.19e-06 | 48 | 39 | 4 | int:NR1I3 | |
| Interaction | THRA interactions | 2.30e-06 | 111 | 39 | 5 | int:THRA | |
| Interaction | SMG7 interactions | 2.32e-06 | 319 | 39 | 7 | int:SMG7 | |
| Interaction | CIITA interactions | 3.80e-06 | 55 | 39 | 4 | int:CIITA | |
| Interaction | TPRX2 interactions | 4.09e-06 | 56 | 39 | 4 | int:TPRX2 | |
| Interaction | VDR interactions | 4.45e-06 | 127 | 39 | 5 | int:VDR | |
| Interaction | SRCAP interactions | 4.45e-06 | 127 | 39 | 5 | int:SRCAP | |
| Interaction | PIAS1 interactions | 4.53e-06 | 353 | 39 | 7 | int:PIAS1 | |
| Interaction | CXXC1 interactions | 5.38e-06 | 132 | 39 | 5 | int:CXXC1 | |
| Interaction | NCOR1 interactions | 5.44e-06 | 363 | 39 | 7 | int:NCOR1 | |
| Interaction | MYB interactions | 5.58e-06 | 133 | 39 | 5 | int:MYB | |
| Interaction | SMAD1 interactions | 6.76e-06 | 243 | 39 | 6 | int:SMAD1 | |
| Interaction | SOX15 interactions | 7.42e-06 | 141 | 39 | 5 | int:SOX15 | |
| Interaction | TLX2 interactions | 7.68e-06 | 142 | 39 | 5 | int:TLX2 | |
| Interaction | ASF1A interactions | 7.77e-06 | 249 | 39 | 6 | int:ASF1A | |
| Interaction | SOX2 interactions | SMARCA2 NCOA3 ZNF384 NCOR2 NCOA6 ZFHX3 ARID1B KMT2D RUNX2 SATB1 EP400 ATXN1 | 9.48e-06 | 1422 | 39 | 12 | int:SOX2 |
| Interaction | PSME3 interactions | 9.91e-06 | 398 | 39 | 7 | int:PSME3 | |
| Interaction | FOXP2 interactions | 1.00e-05 | 70 | 39 | 4 | int:FOXP2 | |
| Interaction | ESRRB interactions | 1.04e-05 | 262 | 39 | 6 | int:ESRRB | |
| Interaction | NCOR2 interactions | 1.08e-05 | 264 | 39 | 6 | int:NCOR2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr16q22 | 5.52e-04 | 183 | 40 | 3 | chr16q22 | |
| GeneFamily | Ataxins|Trinucleotide repeat containing | MED15 MAGI1 NCOA3 ZNF384 NCOR2 KMT2D EP400 FOXP2 NUMBL ATXN2 MAML3 MED12 | 1.05e-28 | 25 | 29 | 12 | 775 |
| GeneFamily | Ataxins|MJD deubiquinating enzymes | 7.40e-08 | 6 | 29 | 3 | 411 | |
| GeneFamily | Zinc fingers ZZ-type|Lysine acetyltransferases | 3.33e-04 | 17 | 29 | 2 | 486 | |
| GeneFamily | Cyclins|Mediator complex | 1.27e-03 | 33 | 29 | 2 | 1061 | |
| GeneFamily | GATA zinc finger domain containing|Myb/SANT domain containing | 3.25e-03 | 53 | 29 | 2 | 532 | |
| Coexpression | DACOSTA_UV_RESPONSE_VIA_ERCC3_DN | SMARCA2 NCOA3 NCOR2 ZFHX3 VEZF1 BMP2K ATXN1 ATXN2 MN1 CREBBP | 3.52e-07 | 856 | 39 | 10 | M4500 |
| Coexpression | LAKE_ADULT_KIDNEY_C16_COLLECTING_SYSTEM_PRINCIPAL_CELLS_CORTEX | 2.08e-06 | 141 | 39 | 5 | M39235 | |
| Coexpression | TABULA_MURIS_SENIS_MESENTERIC_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING | 6.28e-06 | 685 | 39 | 8 | MM3782 | |
| Coexpression | BUSSLINGER_GASTRIC_IMMUNE_CELLS | SMARCA2 NCOA3 KMT2D RUNX2 EP400 VEZF1 NFAT5 ATXN1 PHLDA1 CREBBP DENND4B | 7.48e-06 | 1492 | 39 | 11 | M40023 |
| Coexpression | GSE360_L_DONOVANI_VS_B_MALAYI_LOW_DOSE_MAC_DN | 1.12e-05 | 199 | 39 | 5 | M5240 | |
| Coexpression | GSE40666_UNTREATED_VS_IFNA_STIM_STAT4_KO_EFFECTOR_CD8_TCELL_90MIN_DN | 1.12e-05 | 199 | 39 | 5 | M9236 | |
| Coexpression | GSE12845_IGD_POS_VS_NEG_BLOOD_BCELL_UP | 1.12e-05 | 199 | 39 | 5 | M3182 | |
| Coexpression | GSE8621_UNSTIM_VS_LPS_PRIMED_AND_LPS_STIM_MACROPHAGE_DN | 1.12e-05 | 199 | 39 | 5 | M6987 | |
| Coexpression | GSE31082_DN_VS_CD4_SP_THYMOCYTE_DN | 1.15e-05 | 200 | 39 | 5 | M5059 | |
| Coexpression | GSE41867_DAY8_VS_DAY15_LCMV_CLONE13_EFFECTOR_CD8_TCELL_UP | 1.15e-05 | 200 | 39 | 5 | M9449 | |
| Coexpression | LAKE_ADULT_KIDNEY_C17_COLLECTING_SYSTEM_PCS_STRESSED_DISSOC_SUBSET | 2.76e-05 | 240 | 39 | 5 | M39236 | |
| Coexpression | TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING | 5.00e-05 | 272 | 39 | 5 | MM3825 | |
| Coexpression | ZHOU_INFLAMMATORY_RESPONSE_LIVE_UP | 5.12e-05 | 452 | 39 | 6 | M18685 | |
| Coexpression | KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_UP | 6.17e-05 | 942 | 39 | 8 | M8144 | |
| Coexpression | SCHEIDEREIT_IKK_INTERACTING_PROTEINS | 6.78e-05 | 53 | 39 | 3 | M6303 | |
| Coexpression | KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP | 1.33e-04 | 778 | 39 | 7 | M17915 | |
| Coexpression | GSE37532_WT_VS_PPARG_KO_LN_TREG_UP | 1.34e-04 | 176 | 39 | 4 | M8952 | |
| Coexpression | OKUMURA_INFLAMMATORY_RESPONSE_LPS | 1.53e-04 | 182 | 39 | 4 | M1911 | |
| Coexpression | GSE11057_EFF_MEM_VS_CENT_MEM_CD4_TCELL_DN | 1.77e-04 | 189 | 39 | 4 | M3112 | |
| Coexpression | GSE46025_WT_VS_FOXO1_KO_KLRG1_LOW_CD8_EFFECTOR_TCELL_DN | 1.95e-04 | 194 | 39 | 4 | M9876 | |
| Coexpression | VEGF_A_UP.V1_UP | 1.99e-04 | 195 | 39 | 4 | M2676 | |
| Coexpression | GUO_HEX_TARGETS_UP | 2.14e-04 | 78 | 39 | 3 | M1436 | |
| Coexpression | GSE7831_1H_VS_4H_INFLUENZA_STIM_PDC_DN | 2.15e-04 | 199 | 39 | 4 | M6964 | |
| Coexpression | GSE31082_DN_VS_CD8_SP_THYMOCYTE_DN | 2.20e-04 | 200 | 39 | 4 | M5063 | |
| Coexpression | GSE40655_FOXO1_KO_VS_WT_NTREG_UP | 2.20e-04 | 200 | 39 | 4 | M9439 | |
| Coexpression | GSE26669_CTRL_VS_COSTIM_BLOCK_MLR_CD8_TCELL_DN | 2.20e-04 | 200 | 39 | 4 | M4667 | |
| Coexpression | GSE17301_CTRL_VS_48H_ACD3_ACD28_IFNA5_STIM_CD8_TCELL_UP | 2.20e-04 | 200 | 39 | 4 | M8050 | |
| Coexpression | GSE15330_WT_VS_IKAROS_KO_GRANULOCYTE_MONOCYTE_PROGENITOR_DN | 2.20e-04 | 200 | 39 | 4 | M7028 | |
| Coexpression | GSE27786_ERYTHROBLAST_VS_NEUTROPHIL_DN | 2.20e-04 | 200 | 39 | 4 | M4876 | |
| Coexpression | GSE360_CTRL_VS_L_DONOVANI_MAC_UP | 2.20e-04 | 200 | 39 | 4 | M5157 | |
| Coexpression | GSE40273_GATA1_KO_VS_WT_TREG_DN | 2.20e-04 | 200 | 39 | 4 | M9133 | |
| Coexpression | GUO_HEX_TARGETS_UP | 2.31e-04 | 80 | 39 | 3 | MM626 | |
| Coexpression | FAN_EMBRYONIC_CTX_EX_2_EXCITATORY_NEURON | 2.55e-04 | 16 | 39 | 2 | M39025 | |
| Coexpression | TABULA_MURIS_SENIS_KIDNEY_KIDNEY_COLLECTING_DUCT_PRINCIPAL_CELL_AGEING | 2.83e-04 | 394 | 39 | 5 | MM3724 | |
| Coexpression | SCHEIDEREIT_IKK_TARGETS | 3.25e-04 | 18 | 39 | 2 | M17115 | |
| Coexpression | LU_IL4_SIGNALING | 3.38e-04 | 91 | 39 | 3 | M10558 | |
| Coexpression | KANG_DOXORUBICIN_RESISTANCE_DN | 3.63e-04 | 19 | 39 | 2 | M3323 | |
| Coexpression | HOEBEKE_LYMPHOID_STEM_CELL_UP | 4.08e-04 | 97 | 39 | 3 | M14698 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_top-relative-expression-ranked_1000 | 1.13e-05 | 801 | 39 | 9 | gudmap_developingGonad_e14.5_ epididymis_1000 | |
| CoexpressionAtlas | gamma delta T cells, Tgd.vg2+.act.Sp, TCRd+ Vg2+ CD44+, Spleen, avg-3 | 7.74e-05 | 395 | 39 | 6 | GSM476678_500 | |
| CoexpressionAtlas | DevelopingGonad_e16.5_epididymis_emap-29702_top-relative-expression-ranked_1000 | 7.82e-05 | 790 | 39 | 8 | gudmap_developingGonad_e16.5_epididymis_1000 | |
| CoexpressionAtlas | DevelopingLowerUrinaryTract_e14.5_ Genital tubercle F_emap-6706_top-relative-expression-ranked_500 | 1.20e-04 | 428 | 39 | 6 | gudmap_developingLowerUrinaryTract_e14.5_ Genital tubercle F_500 | |
| CoexpressionAtlas | DevelopingGonad_e14.5_ epididymis_emap-29141_k-means-cluster#3_top-relative-expression-ranked_1000 | 1.41e-04 | 275 | 39 | 5 | gudmap_developingGonad_e14.5_ epididymis_1000_k3 | |
| ToppCell | Bronchial-NucSeq|Bronchial / Cell types per location group and 10X technology with lineage, and cell group designations | 1.83e-08 | 196 | 39 | 6 | ab53c742866945545a92e2e61850d63c80d9a2a6 | |
| ToppCell | Parenchymal-NucSeq|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations | 1.95e-08 | 198 | 39 | 6 | 1996373bdccc55aac347d349bd22f6aad6d0c668 | |
| ToppCell | Tracheal-NucSeq|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations | 2.01e-08 | 199 | 39 | 6 | 94b94b17ca18b8dc27b91da1f2ccf89e03cc7035 | |
| ToppCell | pdx|World / Sample and Cell Type and Tumor Cluster (all cells) | 5.88e-07 | 186 | 39 | 5 | de8e538c8767d41b8a52f5e58ba1affd4e7244c4 | |
| ToppCell | pdx-Tumor_cells|World / Sample and Cell Type and Tumor Cluster (all cells) | 5.88e-07 | 186 | 39 | 5 | 0b88a87158a9ca8de3bf40a4ff1687150707a5f0 | |
| ToppCell | renal_medulla_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group | 6.36e-07 | 189 | 39 | 5 | 830d9cd0dd706bce22eb2416f07b2c31c870a05a | |
| ToppCell | nucseq|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 7.05e-07 | 193 | 39 | 5 | 779276e775cb2492e8dd36436295a536084a6415 | |
| ToppCell | IPF-Lymphoid-T|Lymphoid / Disease state, Lineage and Cell class | 7.61e-07 | 196 | 39 | 5 | 6e70c48a63d9673eb16b0847c1bd88eecc2f7a3c | |
| ToppCell | TCGA-Peripheral_Nervous_System-Primary_Tumor-Paraganglioma-Paraganglioma-3|TCGA-Peripheral_Nervous_System / Sample_Type by Project: Shred V9 | 5.88e-06 | 135 | 39 | 4 | ac20133d4a36f48338b45bffb13e842cb66f83ad | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-1M-IPC_like|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type. | 1.04e-05 | 156 | 39 | 4 | 7e6805ebc7bc2f9c5965321d16922c155719970f | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-1M-IPC_like-IPs_and_early_cortical_neurons|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type. | 1.04e-05 | 156 | 39 | 4 | 741de05295b2d012ac8576378f37709a97c8fb50 | |
| ToppCell | CV-Severe-7|CV / Virus stimulation, Condition and Cluster | 1.67e-05 | 176 | 39 | 4 | 3de0c7d77210049e5616db21eed1490a17a5ec2d | |
| ToppCell | CV-Severe-7|Severe / Virus stimulation, Condition and Cluster | 1.71e-05 | 177 | 39 | 4 | 82fdd6185b368f54f03de389427cbe3071d21a99 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L4_RORB_CCDC168|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 1.83e-05 | 180 | 39 | 4 | a407376209d80177bf7fc4200219030c83cb5f14 | |
| ToppCell | pdx-Tumor_cells-T0|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 2.03e-05 | 185 | 39 | 4 | 1d874608aa2062024323512f68889219471b2f00 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.12e-05 | 187 | 39 | 4 | d2ffb2f34f07b0dd5d3cb3ee0275f46ebecf4146 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_CA4|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.17e-05 | 188 | 39 | 4 | ee572246e0c2f41bdbc29a03edc67b831af95c09 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.30e-05 | 191 | 39 | 4 | d0e9afe7b6334dd515d3e68892efdc76347a55e5 | |
| ToppCell | renal_cortex_nuclei|World / Celltypes from Cells and Nuclei per compartment and clinical group | 2.35e-05 | 192 | 39 | 4 | e8cc4d08fcfceeab75a02558817e4ccd7dbafe3a | |
| ToppCell | LA-14._Fibroblast_III|LA / Chamber and Cluster_Paper | 2.40e-05 | 193 | 39 | 4 | 7426c291bac59e539c427bcaae18abc7d397d44e | |
| ToppCell | LA-14._Fibroblast_III|World / Chamber and Cluster_Paper | 2.45e-05 | 194 | 39 | 4 | 803fa83ceada17c38ca9f933b888f7e7b0b90761 | |
| ToppCell | RA-02._Fibroblast_II|RA / Chamber and Cluster_Paper | 2.50e-05 | 195 | 39 | 4 | 6a02ebbeb3199447ddce64d92d8809436e040eba | |
| ToppCell | Control-Lymphoid-T|Lymphoid / Disease state, Lineage and Cell class | 2.50e-05 | 195 | 39 | 4 | 6687e579582d7a239bee80846de0cf827a6f6a62 | |
| ToppCell | LA-02._Fibroblast_II|World / Chamber and Cluster_Paper | 2.50e-05 | 195 | 39 | 4 | a78b605b49acd8c9d68716266ca269dafcd910b9 | |
| ToppCell | COPD-Lymphoid-T|Lymphoid / Disease state, Lineage and Cell class | 2.55e-05 | 196 | 39 | 4 | c9bdd505c3ab380ed7b272aa518df31a0a706a06 | |
| ToppCell | 10x_3'_v3-lymph_node_(10x_3'_v3)-lymphocytic-T_lymphocytic-type_I_NK_T_cell|lymph_node_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.60e-05 | 197 | 39 | 4 | 51340570667914bffec741c72a8d09cc46abb8e8 | |
| ToppCell | Hematolymphoid-Microglia|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | 21bcca3b670fe9bac034aef2275d3de4a9a73e2b | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-PAX6-CDH12|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | c74bc12e13d002dedaaf75a2244ec111e47524e1 | |
| ToppCell | Hematolymphoid-Microglia-TYROBP----L1-3|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | a20dce14f94777687aad57d6fbe3258ad376f63f | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-PAX6-CDH12-L1-2|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | ead9eb579bb25fde05fc15602e3d05ab6617f7ac | |
| ToppCell | Hematolymphoid-Microglia-TYROBP--|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | dc344b3ec51d506952e38f0b3a7795d65f9dd4eb | |
| ToppCell | Hematolymphoid-Microglia-TYROBP---|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | a8646d0fca99f10827c2d2a12e584660ef7155f1 | |
| ToppCell | Hematolymphoid-Microglia-TYROBP-|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | 3bba5219453322198e8fdb0921d5f8c403598751 | |
| ToppCell | Hematolymphoid-Microglia-TYROBP|Hematolymphoid / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | 33036d21c1c82109284473a515c4f890b33fdd5c | |
| ToppCell | Neuronal-Inhibitory-iA-iA_1(SST_PAX6)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 2.76e-05 | 200 | 39 | 4 | d0167f96314be78b6d867bbcc6e4396071d931b8 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-Neurons|GW26 / Sample Type, Dataset, Time_group, and Cell type. | 2.28e-04 | 136 | 39 | 3 | b46450292e0cd549eb3bafdd3fed22f41d85bfbe | |
| ToppCell | 356C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 3.28e-04 | 154 | 39 | 3 | 692eb053620db86d301b09bf743ab45fccc245be | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Mesenchymal-fibroblastic-Stromal_2_(NPY+)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.47e-04 | 157 | 39 | 3 | 1e3a4a7193d95f09d71c2dfe704b8e626c6d9624 | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Lymphocytic-Epcam____proximal_tube_epithelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.54e-04 | 158 | 39 | 3 | 1d78578dc1f8ba43dacdccae1082c0b9d749f64d | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.95e-04 | 164 | 39 | 3 | d167c7a987b9b35d1e7725c803df4f9cd5380e47 | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5|TCGA-Ovary / Sample_Type by Project: Shred V9 | 4.09e-04 | 166 | 39 | 3 | 32d2eaf8a5d03881bf74d680825af2d5110b082d | |
| ToppCell | COPD-Lymphoid-ILC_B|Lymphoid / Disease state, Lineage and Cell class | 4.09e-04 | 166 | 39 | 3 | e2cad1db536d5ad5a34c337c19b5e7d1a2851552 | |
| ToppCell | Substantia_nigra-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Th|Substantia_nigra / BrainAtlas - Mouse McCarroll V32 | 4.09e-04 | 166 | 39 | 3 | 6a6ed5c7a43fee9a8a9be42dfa99303815b8e8ef | |
| ToppCell | 3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor|lymph-node_spleen / Manually curated celltypes from each tissue | 4.16e-04 | 167 | 39 | 3 | cb396f3edb9e8fdc316091e8e193dbba50e0be0c | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-T_lymphocytic-effector_CD4-positive,_alpha-beta_T_cell|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.23e-04 | 168 | 39 | 3 | 07be11b6f0f37106e219692db5795c6dd32807c9 | |
| ToppCell | Mild/Remission-B_naive-4|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 4.31e-04 | 169 | 39 | 3 | c3a6179a64589a370108fea809b157839347759c | |
| ToppCell | RA-01._Fibroblast_I|RA / Chamber and Cluster_Paper | 4.31e-04 | 169 | 39 | 3 | 6373562ab3b1765060212a6a53d6543e7e942e80 | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_Invariant-Inducer-like|bone_marrow / Manually curated celltypes from each tissue | 4.46e-04 | 171 | 39 | 3 | 2977cffc146470733b5cfd8a1aa80d9346d4804d | |
| ToppCell | normal_Lung-T/NK_cells-Exhausted_Tfh|normal_Lung / Location, Cell class and cell subclass | 4.61e-04 | 173 | 39 | 3 | e8ead6c51c41dbd43c717ba9d1a7a0ab39c79330 | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-Ccr7+_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.69e-04 | 174 | 39 | 3 | 7be0c6248e77f2d0260b852b01e17892f7828f1b | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_GRIP2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.77e-04 | 175 | 39 | 3 | 0c648e7f67ffbe3b476a2ca77d246554f8cd1882 | |
| ToppCell | 5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.93e-04 | 177 | 39 | 3 | bd602db857f37869ef76d14c05ef522c509f08ee | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.93e-04 | 177 | 39 | 3 | da8802a6351d3e510822f82e2fde8a4314a2216e | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 5.01e-04 | 178 | 39 | 3 | c20f050344a2e120e685e2a7fe36c6dfc1dc37b6 | |
| ToppCell | Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_PAX6-Inh_L1_PAX6_CA4|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.01e-04 | 178 | 39 | 3 | e86ed30652c2de70f16430f04b78789b87df4af2 | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_Invariant-Inducer-like-MAIT|bone_marrow / Manually curated celltypes from each tissue | 5.01e-04 | 178 | 39 | 3 | 7ac71e245864be2e8daecf555ff68235bd05827c | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c02-GPR183|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.01e-04 | 178 | 39 | 3 | 31c847d7f7aa0f6d820afbb45d507992f5e9dc2f | |
| ToppCell | LA-01._Fibroblast_I|LA / Chamber and Cluster_Paper | 5.09e-04 | 179 | 39 | 3 | dcb6ec9ae72b13fe388b72dace2815293fafe8ee | |
| ToppCell | 356C-Lymphocytic-CD4_T-cell-CD4+_Effector_T_cell-1|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 5.18e-04 | 180 | 39 | 3 | f24d4cbba4cb50fce3b3d9c4629aa856d9b05358 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.18e-04 | 180 | 39 | 3 | e8841ef1239f9ee73ac4f4e11faca0742694f368 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2-Exc_L6_FEZF2_VWA2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.35e-04 | 182 | 39 | 3 | 72e65a23cd36085bc880087d3cae92395de918a1 | |
| ToppCell | 5'-Adult-SmallIntestine-Hematopoietic-Plasma_cells|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.35e-04 | 182 | 39 | 3 | a00abff41c12b71d5860c494b8c722d649fd5f36 | |
| ToppCell | 5'-Adult-SmallIntestine-Hematopoietic-Plasma_cells-IgA_plasma_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.35e-04 | 182 | 39 | 3 | 626aabfd9ac662c1d189f7c4b660482914d9e669 | |
| ToppCell | 5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.35e-04 | 182 | 39 | 3 | 53c267ee327e116dbd89d5927ed3bdf78d25ee62 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT_L6_FEZF2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 5.35e-04 | 182 | 39 | 3 | 05c167158815bf25d509df59ab386e1990712765 | |
| ToppCell | Control-Neu_4|World / 5 Neutrophil clusters in COVID-19 patients | 5.52e-04 | 184 | 39 | 3 | ce7f044956613118ee2e9fb6af2455c3166cb414 | |
| ToppCell | normal-na-Lymphocytic_T-T8_naive-male|normal / PBMC cell types (v2) per disease, treatment status, and sex | 5.52e-04 | 184 | 39 | 3 | 4a81190b36d197736663e6177d3b76c1cb6282d6 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like|lymph-node_spleen / Manually curated celltypes from each tissue | 5.52e-04 | 184 | 39 | 3 | d97471a4fe17cba6880ccf1a04cc00c741558124 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like-ILC3|lymph-node_spleen / Manually curated celltypes from each tissue | 5.52e-04 | 184 | 39 | 3 | 479e60f76c191253e23699c9dd7ef7efc08c59ad | |
| ToppCell | wk_15-18-Epithelial-Distal_epithelial_progenitor-epi-tip_intermediate|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 5.61e-04 | 185 | 39 | 3 | 636505a3d96f75d951ab42bcf8af6ae07abc732d | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_D3|NK_cells / Donor, Lineage, Cell class and subclass (all cells) | 5.61e-04 | 185 | 39 | 3 | 4a5e70ac41e5f3b25a773304ffef3c2a3dd5549d | |
| ToppCell | 5'-Adult-LymphNode-Hematopoietic-T_cells-ILC3|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 5.61e-04 | 185 | 39 | 3 | 7d6954bb04368ec62b284ba6c3021a15fbdfdee6 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.61e-04 | 185 | 39 | 3 | a2cae8c657e4f4d121476798e424876f7e247973 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-DN4_thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.61e-04 | 185 | 39 | 3 | d50406a9a5b8d75110ba5985741aa2293950c543 | |
| ToppCell | CV-Moderate-7|Moderate / Virus stimulation, Condition and Cluster | 5.61e-04 | 185 | 39 | 3 | a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f | |
| ToppCell | droplet-Heart-4Chambers-21m-Endothelial-leukocyte|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.61e-04 | 185 | 39 | 3 | bb5a4cf93534b9bcd0923f314c389d571e91e7f8 | |
| ToppCell | droplet-Lung-LUNG-30m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.69e-04 | 186 | 39 | 3 | f23f21781a758541f59c06efa7739d26a03fb478 | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-21m|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.69e-04 | 186 | 39 | 3 | bd1185592aedebccd1007dbf2dd2f549fcdf9f42 | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-innate_lymphocytic|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 5.69e-04 | 186 | 39 | 3 | 855c2e5a8a6cf94c7de31982e0e2416f924439d3 | |
| ToppCell | droplet-Lung-LUNG-30m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.69e-04 | 186 | 39 | 3 | 0de87109da9324c597fadf2eb782f0f158afe832 | |
| ToppCell | LA-01._Fibroblast_I|World / Chamber and Cluster_Paper | 5.78e-04 | 187 | 39 | 3 | 4ea486991f66c29728d127171a07b81404ec0b78 | |
| ToppCell | PBMC-Mild-cDC_5|Mild / Compartment, Disease Groups and Clusters | 5.78e-04 | 187 | 39 | 3 | 0afef5baf3752314dbfb024790347d5e51f9b84b | |
| ToppCell | 343B-Lymphocytic-ILC-ILC-1|343B / Donor, Lineage, Cell class and subclass (all cells) | 5.87e-04 | 188 | 39 | 3 | 8f6b45ad82bde65e044d17f0edbc3db90d457915 | |
| ToppCell | COPD-Endothelial-VE_Capillary_A|Endothelial / Disease state, Lineage and Cell class | 5.87e-04 | 188 | 39 | 3 | 1aa0e35b1c28ac847886fece16c3ef7fc6fcdd51 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD|kidney_cells / Celltypes from Cells and Nuclei per compartment and clinical group | 5.87e-04 | 188 | 39 | 3 | 90188b60ff893754f7938fe8edab79758827168e | |
| ToppCell | LV-14._Fibroblast_III|World / Chamber and Cluster_Paper | 5.97e-04 | 189 | 39 | 3 | 3922135d1f6fc768d71ba3b465585fead6ea68a8 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.97e-04 | 189 | 39 | 3 | e9df7ecd36bee1fedce23bb188c68a94fa60462c | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_Invariant-Inducer-like|bone_marrow / Manually curated celltypes from each tissue | 5.97e-04 | 189 | 39 | 3 | ac2995e599f3d1813218479dc515b1d612c0ef8b | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-21m-Epithelial|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.97e-04 | 189 | 39 | 3 | 965e0e388251e7318f8b463816dc96ccb4658677 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 5.97e-04 | 189 | 39 | 3 | 904b8337e2cabac2f0bf5dad5598fc429581ed81 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW09-Neuronal-Neuron|GW09 / Sample Type, Dataset, Time_group, and Cell type. | 5.97e-04 | 189 | 39 | 3 | 3717d1148e26ac78a26aea0ca1dbfbb9d3668877 | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_Invariant-Inducer-like-MAIT|lymph-node_spleen / Manually curated celltypes from each tissue | 5.97e-04 | 189 | 39 | 3 | afe3a4fe7c10eeeb7064129778d940269c9acbef | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-4M-Neuronal-ventral_progenitors_and_neurons_1|Organoid-4M / Sample Type, Dataset, Time_group, and Cell type. | 6.06e-04 | 190 | 39 | 3 | 6e92c78799f34b31d098854503c796edb0dc7f80 | |
| ToppCell | LV-01._Fibroblast_I|World / Chamber and Cluster_Paper | 6.06e-04 | 190 | 39 | 3 | 12992ec80a7b4f4f17de693f0719ee061a9918fd | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D175|Adult / Lineage, Cell type, age group and donor | 6.06e-04 | 190 | 39 | 3 | 7dcca3469f3a3b70db0420cb94f7765f39492f06 | |
| ToppCell | MS-CD8-antiviral_CD4|MS / Condition, Cell_class and T cell subcluster | 6.06e-04 | 190 | 39 | 3 | 8c831c4560b8e70f92b4c15644fea39f7f7afcf2 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-3.5_mon-Neuronal-Immature_INs|3.5_mon / Sample Type, Dataset, Time_group, and Cell type. | 6.06e-04 | 190 | 39 | 3 | 842760bfe0a52e67bad800efa7d99448a4a23ebb | |
| ToppCell | droplet-Lung-30m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 6.15e-04 | 191 | 39 | 3 | 51cff0594ac7ad8c065c8ea2301f8c149bd062b4 | |
| ToppCell | LV-02._Fibroblast_II|World / Chamber and Cluster_Paper | 6.15e-04 | 191 | 39 | 3 | d36565257ccba8c1bbed2c1c01be66a9cbb5f834 | |
| ToppCell | RV-01._Fibroblast_I|World / Chamber and Cluster_Paper | 6.15e-04 | 191 | 39 | 3 | 70c067c54084bfb02c29bab085f4defd477194fb | |
| Drug | glutamin | KCNN3 NCOA3 ZNF384 NCOR2 POU3F2 IRF2BPL ATN1 FOXP2 NFAT5 ATXN1 CREBBP AR HTT TBP THAP11 | 5.07e-16 | 461 | 39 | 15 | CID000000738 |
| Drug | 2-cyanoacetamide | 1.03e-08 | 162 | 39 | 7 | CID000007898 | |
| Drug | AC1L2E0P | 4.27e-08 | 307 | 39 | 8 | CID000019390 | |
| Drug | l-Alanyl-l-glutamine | 2.02e-07 | 150 | 39 | 6 | CID000123935 | |
| Drug | 1 C2 | 7.56e-07 | 100 | 39 | 5 | CID005327152 | |
| Drug | pirimicarb | 1.60e-06 | 50 | 39 | 4 | CID000031645 | |
| Drug | Dihydrotestosterone | 2.32e-06 | 360 | 39 | 7 | ctd:D013196 | |
| Drug | A25618 | 5.06e-06 | 777 | 39 | 9 | CID000005562 | |
| Drug | AC1ND2OB | 5.55e-06 | 265 | 39 | 6 | CID004568637 | |
| Drug | stanolone benzoate | 8.57e-06 | 3 | 39 | 2 | ctd:C040109 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 1.03e-05 | 170 | 39 | 5 | 1050_DN | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 1uM; MCF7; HT_HG-U133A_EA | 1.09e-05 | 172 | 39 | 5 | 1072_DN | |
| Drug | levodopa/carbidopa | 1.18e-05 | 26 | 39 | 3 | CID000104778 | |
| Drug | lithocholyltaurine | 1.18e-05 | 175 | 39 | 5 | CID000010595 | |
| Drug | Trichostatin A, Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA | 1.28e-05 | 178 | 39 | 5 | 1112_DN | |
| Drug | Dipivefrin hydrochloride [64019-93-8]; Up 200; 10.4uM; HL60; HG-U133A | 1.35e-05 | 180 | 39 | 5 | 1752_UP | |
| Drug | vorinostat | 1.46e-05 | 314 | 39 | 6 | CID000005311 | |
| Drug | NSC-364372 | 1.60e-05 | 484 | 39 | 7 | CID000435143 | |
| Drug | trenbolone acetate | 1.65e-05 | 29 | 39 | 3 | CID000066359 | |
| Drug | 9,10-dihydrophenanthrene | 1.71e-05 | 4 | 39 | 2 | CID000013058 | |
| Drug | E)-4-hydroxytamoxifen | 2.09e-05 | 197 | 39 | 5 | CID000063062 | |
| Drug | Sulfanilamide [63-74-1]; Down 200; 23.2uM; MCF7; HT_HG-U133A | 2.14e-05 | 198 | 39 | 5 | 3449_DN | |
| Drug | ahz | 2.23e-05 | 32 | 39 | 3 | CID000656929 | |
| Drug | dimethyl phthalate | 2.34e-05 | 714 | 39 | 8 | ctd:C024629 | |
| Drug | AC1L9FY1 | 2.66e-05 | 101 | 39 | 4 | CID000444218 | |
| Drug | AC1L3UEY | 4.14e-05 | 113 | 39 | 4 | CID000122342 | |
| Drug | butamben | 4.27e-05 | 6 | 39 | 2 | ctd:C004605 | |
| Drug | androstan-3-ol | 4.27e-05 | 6 | 39 | 2 | ctd:C000658 | |
| Drug | Androstenedione | 6.27e-05 | 45 | 39 | 3 | ctd:D000735 | |
| Drug | Spotlight | 6.33e-05 | 126 | 39 | 4 | CID000086222 | |
| Drug | 5'-pCAA-3' | 6.33e-05 | 126 | 39 | 4 | CID000482140 | |
| Drug | DMAB | 7.81e-05 | 133 | 39 | 4 | CID000006053 | |
| Drug | fluorosilicate | 7.95e-05 | 8 | 39 | 2 | CID000028117 | |
| Drug | AC1OA6HT | 7.95e-05 | 8 | 39 | 2 | CID005493749 | |
| Drug | NSC71948 | 9.01e-05 | 138 | 39 | 4 | CID000415676 | |
| Drug | AC1LA6KT | 9.14e-05 | 51 | 39 | 3 | CID000508110 | |
| Drug | alanine | 9.19e-05 | 269 | 39 | 5 | CID000000602 | |
| Drug | tris(chloroethyl)phosphate | 1.15e-04 | 55 | 39 | 3 | ctd:C031324 | |
| Drug | Azaguanine-8 [134-58-7]; Up 200; 26.2uM; HL60; HT_HG-U133A | 1.56e-04 | 159 | 39 | 4 | 1833_UP | |
| Drug | Scytolone | 1.56e-04 | 11 | 39 | 2 | CID000162567 | |
| Drug | chrysamine | 1.80e-04 | 64 | 39 | 3 | CID006011258 | |
| Drug | SAHA; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 2.25e-04 | 175 | 39 | 4 | 1058_DN | |
| Drug | 3-nitropropionic acid | 2.40e-04 | 178 | 39 | 4 | CID000001678 | |
| Drug | cystamine | 2.56e-04 | 181 | 39 | 4 | CID000002915 | |
| Drug | butylurethane | 2.57e-04 | 14 | 39 | 2 | CID000011577 | |
| Drug | Methotrimeprazine maleat salt [7104-38-3]; Up 200; 9uM; PC3; HT_HG-U133A | 2.95e-04 | 188 | 39 | 4 | 3701_UP | |
| Drug | Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; PC3; HT_HG-U133A | 3.01e-04 | 189 | 39 | 4 | 4304_UP | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HG-U133A | 3.08e-04 | 190 | 39 | 4 | 1400_UP | |
| Drug | AC1L97MU | 3.11e-04 | 77 | 39 | 3 | CID000414413 | |
| Drug | Tranylcypromine hydrochloride [1986-47-6]; Up 200; 23.6uM; HL60; HG-U133A | 3.14e-04 | 191 | 39 | 4 | 1417_UP | |
| Drug | Mesalamine [89-57-6]; Down 200; 26.2uM; HL60; HT_HG-U133A | 3.20e-04 | 192 | 39 | 4 | 6162_DN | |
| Drug | Beta-Escin [11072-93-8]; Up 200; 3.2uM; MCF7; HT_HG-U133A | 3.20e-04 | 192 | 39 | 4 | 6050_UP | |
| Drug | Propoxycaine hydrochloride [550-83-4]; Down 200; 12uM; PC3; HT_HG-U133A | 3.20e-04 | 192 | 39 | 4 | 7155_DN | |
| Drug | MAR70 | 3.23e-04 | 78 | 39 | 3 | CID000004013 | |
| Drug | Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; PC3; HT_HG-U133A | 3.26e-04 | 193 | 39 | 4 | 3811_UP | |
| Drug | troglitazone; Down 200; 10uM; PC3; HG-U133A | 3.26e-04 | 193 | 39 | 4 | 431_DN | |
| Drug | Etifenin [63245-28-3]; Down 200; 12.4uM; HL60; HT_HG-U133A | 3.26e-04 | 193 | 39 | 4 | 2477_DN | |
| Drug | Dantrolene sodium salt [14663-23-1]; Down 200; 11.8uM; PC3; HT_HG-U133A | 3.26e-04 | 193 | 39 | 4 | 4343_DN | |
| Drug | Diphenhydramine hydrochloride [147-24-0]; Up 200; 13.8uM; PC3; HT_HG-U133A | 3.26e-04 | 193 | 39 | 4 | 1830_UP | |
| Drug | Mifepristone | 3.30e-04 | 553 | 39 | 6 | ctd:D015735 | |
| Drug | 2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA | 3.33e-04 | 194 | 39 | 4 | 1060_UP | |
| Drug | semustine; Up 200; 100uM; MCF7; HT_HG-U133A | 3.33e-04 | 194 | 39 | 4 | 7487_UP | |
| Drug | canrenone | 3.38e-04 | 16 | 39 | 2 | CID000013789 | |
| Drug | Naphazoline hydrochloride [550-99-2]; Up 200; 16.2uM; HL60; HG-U133A | 3.39e-04 | 195 | 39 | 4 | 1966_UP | |
| Drug | Benfotiamine [22457-89-2]; Up 200; 8.6uM; PC3; HT_HG-U133A | 3.39e-04 | 195 | 39 | 4 | 4312_UP | |
| Drug | Securinine [5610-40-2]; Down 200; 18.4uM; MCF7; HT_HG-U133A | 3.39e-04 | 195 | 39 | 4 | 3470_DN | |
| Drug | Ifenprodil tartrate [23210-58-4]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 3.39e-04 | 195 | 39 | 4 | 7404_DN | |
| Drug | 6-mercaptopurine monohydrate; Down 200; 10uM; PC3; HG-U133A | 3.39e-04 | 195 | 39 | 4 | 667_DN | |
| Drug | Naphazoline hydrochloride [550-99-2]; Down 200; 16.2uM; PC3; HG-U133A | 3.39e-04 | 195 | 39 | 4 | 1886_DN | |
| Drug | Pargyline hydrochloride [306-07-0]; Up 200; 20.4uM; HL60; HG-U133A | 3.46e-04 | 196 | 39 | 4 | 1418_UP | |
| Drug | 5162773; Down 200; 7uM; MCF7; HT_HG-U133A_EA | 3.46e-04 | 196 | 39 | 4 | 892_DN | |
| Drug | AG-012559 [369370-06-9]; Up 200; 10uM; MCF7; HT_HG-U133A | 3.46e-04 | 196 | 39 | 4 | 6889_UP | |
| Drug | Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; PC3; HT_HG-U133A | 3.46e-04 | 196 | 39 | 4 | 4227_DN | |
| Drug | 17-AAG; Down 200; 1uM; PC3; HG-U133A | 3.46e-04 | 196 | 39 | 4 | 432_DN | |
| Drug | Trapidil [15421-84-8]; Down 200; 19.4uM; HL60; HT_HG-U133A | 3.46e-04 | 196 | 39 | 4 | 3136_DN | |
| Drug | Azlocillin sodium salt [37091-65-9]; Down 200; 8.2uM; MCF7; HT_HG-U133A | 3.46e-04 | 196 | 39 | 4 | 3468_DN | |
| Drug | terbutryn | 3.48e-04 | 80 | 39 | 3 | CID000013450 | |
| Drug | Stallimycin | 3.48e-04 | 80 | 39 | 3 | CID000003115 | |
| Drug | (-)-quinpirole hydrochloride; Up 200; 1uM; MCF7; HG-U133A | 3.53e-04 | 197 | 39 | 4 | 456_UP | |
| Drug | Ajmaline [4360-12-7]; Up 200; 12.2uM; HL60; HG-U133A | 3.53e-04 | 197 | 39 | 4 | 1749_UP | |
| Drug | Medrysone [2668-66-8]; Up 200; 11.6uM; PC3; HT_HG-U133A | 3.53e-04 | 197 | 39 | 4 | 4266_UP | |
| Drug | LY294002; Down 200; 10uM; PC3; HG-U133A | 3.53e-04 | 197 | 39 | 4 | 429_DN | |
| Drug | STOCK1N-35874; Down 200; 14uM; PC3; HT_HG-U133A | 3.53e-04 | 197 | 39 | 4 | 6561_DN | |
| Drug | Tridihexethyl chloride; Down 200; 11.4uM; MCF7; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 5486_DN | |
| Drug | Dicumarol [66-76-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 3423_DN | |
| Drug | Rifampicin [13292-46-1]; Up 200; 4.8uM; HL60; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 2487_UP | |
| Drug | GSK-3 Inhibitor IX; Down 200; 0.5uM; PC3; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 6559_DN | |
| Drug | Sulfasalazine [599-79-1]; Up 200; 10uM; HL60; HG-U133A | 3.60e-04 | 198 | 39 | 4 | 1733_UP | |
| Drug | Sulfamonomethoxine [1220-83-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 7200_DN | |
| Drug | raloxifene hydrochloride; Down 200; 0.1uM; MCF7; HG-U133A | 3.60e-04 | 198 | 39 | 4 | 202_DN | |
| Drug | Evoxine [522-11-2]; Up 200; 11.6uM; PC3; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 7380_UP | |
| Drug | 11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A | 3.60e-04 | 198 | 39 | 4 | 7519_DN | |
| Drug | Cefotetan [69712-56-7]; Down 200; 7uM; HL60; HT_HG-U133A | 3.67e-04 | 199 | 39 | 4 | 1319_DN | |
| Drug | Tiletamine hydrochloride; Down 200; 15.4uM; PC3; HT_HG-U133A | 3.67e-04 | 199 | 39 | 4 | 7311_DN | |
| Drug | cyclosarin | 3.67e-04 | 199 | 39 | 4 | CID000064505 | |
| Drug | tamoxifen citrate; Up 200; 1uM; MCF7; HG-U133A | 3.67e-04 | 199 | 39 | 4 | 380_UP | |
| Drug | Cefixime [79350-37-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 3.67e-04 | 199 | 39 | 4 | 4390_DN | |
| Drug | Desipramine hydrochloride [58-28-6]; Up 200; 13.2uM; HL60; HG-U133A | 3.67e-04 | 199 | 39 | 4 | 1596_UP | |
| Drug | SC-58125; Up 200; 10uM; MCF7; HG-U133A | 3.67e-04 | 199 | 39 | 4 | 254_UP | |
| Drug | Carbetapentane citrate [23142-01-0]; Down 200; 7.6uM; PC3; HT_HG-U133A | 3.67e-04 | 199 | 39 | 4 | 4649_DN | |
| Disease | schizophrenia (is_implicated_in) | 6.08e-08 | 78 | 39 | 5 | DOID:5419 (is_implicated_in) | |
| Disease | Adenoid Cystic Carcinoma | 2.12e-07 | 100 | 39 | 5 | C0010606 | |
| Disease | Schizophrenia | 1.75e-06 | 883 | 39 | 9 | C0036341 | |
| Disease | Paroxysmal atrial fibrillation | 1.93e-06 | 156 | 39 | 5 | C0235480 | |
| Disease | familial atrial fibrillation | 1.93e-06 | 156 | 39 | 5 | C3468561 | |
| Disease | Persistent atrial fibrillation | 1.93e-06 | 156 | 39 | 5 | C2585653 | |
| Disease | Atrial Fibrillation | 2.18e-06 | 160 | 39 | 5 | C0004238 | |
| Disease | household income | 2.79e-06 | 304 | 39 | 6 | EFO_0009695 | |
| Disease | Phyllodes Tumor | 1.70e-05 | 5 | 39 | 2 | C0010701 | |
| Disease | Malignant Cystosarcoma Phyllodes | 1.70e-05 | 5 | 39 | 2 | C0600066 | |
| Disease | MENTAL RETARDATION, AUTOSOMAL DOMINANT 12 | 1.70e-05 | 5 | 39 | 2 | C3281201 | |
| Disease | total blood protein measurement | 2.56e-05 | 449 | 39 | 6 | EFO_0004536 | |
| Disease | testosterone measurement | 3.35e-05 | 1275 | 39 | 9 | EFO_0004908 | |
| Disease | lung non-small cell carcinoma (is_implicated_in) | 3.41e-05 | 139 | 39 | 4 | DOID:3908 (is_implicated_in) | |
| Disease | chronic mucus hypersecretion | 3.56e-05 | 7 | 39 | 2 | EFO_0005673 | |
| Disease | Huntington's disease (is_marker_for) | 4.78e-05 | 53 | 39 | 3 | DOID:12858 (is_marker_for) | |
| Disease | prostate cancer (is_marker_for) | 5.35e-05 | 156 | 39 | 4 | DOID:10283 (is_marker_for) | |
| Disease | diet measurement | 5.73e-05 | 1049 | 39 | 8 | EFO_0008111 | |
| Disease | Malignant tumor of prostate | 6.09e-05 | 9 | 39 | 2 | cv:C0376358 | |
| Disease | forced expiratory volume | 6.94e-05 | 789 | 39 | 7 | EFO_0004314 | |
| Disease | Parkinson disease, late-onset | 7.61e-05 | 10 | 39 | 2 | cv:C3160718 | |
| Disease | PARKINSON DISEASE, LATE-ONSET | 7.61e-05 | 10 | 39 | 2 | 168600 | |
| Disease | attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement | 7.63e-05 | 801 | 39 | 7 | EFO_0003888, EFO_0007052, MONDO_0002491 | |
| Disease | schizophrenia, intelligence, self reported educational attainment | 8.94e-05 | 346 | 39 | 5 | EFO_0004337, EFO_0004784, MONDO_0005090 | |
| Disease | breast carcinoma (is_marker_for) | 9.22e-05 | 66 | 39 | 3 | DOID:3459 (is_marker_for) | |
| Disease | polybrominated biphenyl measurement, gestational serum measurement, fetal genotype effect measurement, polybrominated diphenyl ether measurement | 9.29e-05 | 11 | 39 | 2 | EFO_0007959, EFO_0007961, EFO_0007962, EFO_0007964 | |
| Disease | late onset Parkinson's disease (is_implicated_in) | 9.29e-05 | 11 | 39 | 2 | DOID:0060892 (is_implicated_in) | |
| Disease | autosomal dominant cerebellar ataxia (implicated_via_orthology) | 1.11e-04 | 12 | 39 | 2 | DOID:1441 (implicated_via_orthology) | |
| Disease | PARKINSON DISEASE, LATE-ONSET | 1.11e-04 | 12 | 39 | 2 | C3160718 | |
| Disease | Coffin-Siris syndrome | 1.32e-04 | 13 | 39 | 2 | C0265338 | |
| Disease | Prostatic Neoplasms | 1.47e-04 | 616 | 39 | 6 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 1.47e-04 | 616 | 39 | 6 | C0376358 | |
| Disease | sulfate measurement | 1.53e-04 | 14 | 39 | 2 | EFO_0007864 | |
| Disease | Lymphoma, Large-Cell, Follicular | 1.77e-04 | 15 | 39 | 2 | C0079745 | |
| Disease | Lymphoma, Small Cleaved-Cell, Follicular | 1.77e-04 | 15 | 39 | 2 | C0079765 | |
| Disease | Lymphoma, Mixed-Cell, Follicular | 1.77e-04 | 15 | 39 | 2 | C0079758 | |
| Disease | Lymphoma, Follicular, Grade 2 | 1.77e-04 | 15 | 39 | 2 | C1956132 | |
| Disease | Lymphoma, Follicular, Grade 3 | 1.77e-04 | 15 | 39 | 2 | C1956131 | |
| Disease | Lymphoma, Follicular, Grade 1 | 1.77e-04 | 15 | 39 | 2 | C1956130 | |
| Disease | feeling nervous measurement | 2.10e-04 | 87 | 39 | 3 | EFO_0009597 | |
| Disease | major depressive disorder (is_implicated_in) | 2.29e-04 | 17 | 39 | 2 | DOID:1470 (is_implicated_in) | |
| Disease | Feeding difficulties | 2.57e-04 | 18 | 39 | 2 | C0232466 | |
| Disease | acute lymphoblastic leukemia, response to antineoplastic agent | 2.87e-04 | 19 | 39 | 2 | EFO_0000220, GO_0097327 | |
| Disease | neuroticism measurement, wellbeing measurement, depressive symptom measurement | 2.87e-04 | 19 | 39 | 2 | EFO_0007006, EFO_0007660, EFO_0007869 | |
| Disease | diet measurement, HOMA-B | 2.87e-04 | 19 | 39 | 2 | EFO_0004469, EFO_0008111 | |
| Disease | Craniosynostosis | 3.19e-04 | 20 | 39 | 2 | C0010278 | |
| Disease | Lymphoma, Follicular | 3.19e-04 | 20 | 39 | 2 | C0024301 | |
| Disease | attention deficit hyperactivity disorder (is_implicated_in) | 3.19e-04 | 20 | 39 | 2 | DOID:1094 (is_implicated_in) | |
| Disease | gastroesophageal reflux disease | 3.25e-04 | 101 | 39 | 3 | EFO_0003948 | |
| Disease | osteoarthritis, hip, osteoarthritis, knee, total joint arthroplasty | 3.52e-04 | 21 | 39 | 2 | EFO_0004616, EFO_0010726, EFO_1000786 | |
| Disease | Parkinson disease | 3.87e-04 | 22 | 39 | 2 | cv:C0030567 | |
| Disease | frailty measurement | 4.23e-04 | 23 | 39 | 2 | EFO_0009885 | |
| Disease | neuroimaging measurement | 4.48e-04 | 1069 | 39 | 7 | EFO_0004346 | |
| Disease | Neoplasm of the genitourinary tract | 4.61e-04 | 24 | 39 | 2 | cv:C0042065 | |
| Disease | risk-taking behaviour | 4.65e-04 | 764 | 39 | 6 | EFO_0008579 | |
| Disease | Cerebral Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0750935 | |
| Disease | Intracranial Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0750936 | |
| Disease | Pilocytic Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0334583 | |
| Disease | Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0004114 | |
| Disease | Juvenile Pilocytic Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0280783 | |
| Disease | Diffuse Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0280785 | |
| Disease | Grade I Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C1704230 | |
| Disease | Subependymal Giant Cell Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0205768 | |
| Disease | Mixed oligoastrocytoma | 5.01e-04 | 25 | 39 | 2 | C0547065 | |
| Disease | Childhood Cerebral Astrocytoma | 5.01e-04 | 25 | 39 | 2 | C0338070 | |
| Disease | Gemistocytic astrocytoma | 5.42e-04 | 26 | 39 | 2 | C0334581 | |
| Disease | Protoplasmic astrocytoma | 5.42e-04 | 26 | 39 | 2 | C0334580 | |
| Disease | Fibrillary Astrocytoma | 5.42e-04 | 26 | 39 | 2 | C0334582 | |
| Disease | Sezary Syndrome | 5.85e-04 | 27 | 39 | 2 | C0036920 | |
| Disease | Anaplastic astrocytoma | 5.85e-04 | 27 | 39 | 2 | C0334579 | |
| Disease | longevity, healthspan, parental longevity | 6.76e-04 | 29 | 39 | 2 | EFO_0004300, EFO_0007796, EFO_0009762 | |
| Disease | Breast Carcinoma | 6.83e-04 | 538 | 39 | 5 | C0678222 | |
| Disease | smoking status measurement | 7.28e-04 | 1160 | 39 | 7 | EFO_0006527 | |
| Disease | brain measurement, neuroimaging measurement | 7.54e-04 | 550 | 39 | 5 | EFO_0004346, EFO_0004464 | |
| Disease | Hirschsprung Disease | 7.73e-04 | 31 | 39 | 2 | C0019569 | |
| Disease | smoking cessation | 8.77e-04 | 325 | 39 | 4 | EFO_0004319 | |
| Disease | Spinocerebellar Ataxia Type 2 | 9.30e-04 | 34 | 39 | 2 | C0752121 | |
| Disease | Spinocerebellar Ataxia Type 1 | 9.30e-04 | 34 | 39 | 2 | C0752120 | |
| Disease | Spinocerebellar Ataxia Type 5 | 9.30e-04 | 34 | 39 | 2 | C0752123 | |
| Disease | Spinocerebellar Ataxia Type 7 | 9.30e-04 | 34 | 39 | 2 | C0752125 | |
| Disease | Spinocerebellar Ataxia Type 6 (disorder) | 9.30e-04 | 34 | 39 | 2 | C0752124 | |
| Disease | Ataxia, Spinocerebellar | 9.30e-04 | 34 | 39 | 2 | C0087012 | |
| Disease | carbohydrate intake measurement | 9.30e-04 | 34 | 39 | 2 | EFO_0010811 | |
| Disease | Spinocerebellar Ataxia Type 4 | 9.85e-04 | 35 | 39 | 2 | C0752122 | |
| Disease | waist-hip ratio | 1.01e-03 | 1226 | 39 | 7 | EFO_0004343 | |
| Disease | Mitral valve prolapse | 1.04e-03 | 36 | 39 | 2 | HP_0001634 | |
| Disease | smoking behavior | 1.05e-03 | 341 | 39 | 4 | EFO_0004318 | |
| Disease | vital capacity | 1.06e-03 | 1236 | 39 | 7 | EFO_0004312 | |
| Disease | osteoarthritis, knee | 1.20e-03 | 158 | 39 | 3 | EFO_0004616 | |
| Disease | progression free survival, response to carboplatin, methylcobalamin deficiency type cblE, ovarian carcinoma | 1.22e-03 | 39 | 39 | 2 | EFO_0001075, EFO_0004920, GO_0097328, MONDO_0009354 | |
| Disease | dyslexia | 1.28e-03 | 162 | 39 | 3 | EFO_0005424 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QQQQQQQQQQQQQQQ | 2756 | Q96L91 | |
| QQQQQQQQQQQQQQQ | 2761 | Q96L91 | |
| QQQQQQQQQQQQQQQ | 2766 | Q96L91 | |
| QQQQQQQQQQQQQQT | 2771 | Q96L91 | |
| QQQQQQQQQQQQQQQ | 486 | P54259 | |
| QQQQQQQQQQQQQQQ | 2201 | Q92793 | |
| FQQQQQQQQQQQQQQ | 196 | Q8NFD5 | |
| QQQQQQQQQQQQQQH | 201 | Q8NFD5 | |
| HQQQQQQQQQQQQQQ | 211 | P54253 | |
| QQQQQQQQQQQQQQQ | 461 | Q9NSY1 | |
| QQQQQQQQQQQQQQQ | 466 | Q9NSY1 | |
| QQQQQQQQQQQQQQQ | 471 | Q9NSY1 | |
| AQQQQQQQQQQQQQQ | 426 | Q9Y6R0 | |
| QQQQQQQQQQQQQQQ | 431 | Q9Y6R0 | |
| QQQQQQQQQQQQQQQ | 496 | Q9Y618 | |
| EQQQQQQQQQQQQQQ | 401 | Q96QZ7 | |
| QQQQQQQQQQQQQQQ | 406 | Q96QZ7 | |
| QQQQQQQQQQQQQQQ | 486 | Q96JK9 | |
| QQQQQQQQQQQQQQQ | 491 | Q96JK9 | |
| QQQQQQQQQQQQQQQ | 496 | Q96JK9 | |
| QQQQQQQQQQQQQQQ | 636 | Q96JK9 | |
| QQQQQQQQQQQQQQQ | 166 | Q99700 | |
| QQQQQQQQQQQQQQQ | 171 | Q99700 | |
| QQQQQQQQQQQQQQQ | 106 | Q9H1B7 | |
| QQQQQQQQQQQQQQQ | 111 | Q9H1B7 | |
| QQQQQQQQQQQQQQL | 71 | C9JC47 | |
| LQQQQQQQQQQQQQQ | 66 | Q9UGI6 | |
| LQQQQQQQQQQQQQQ | 151 | O15409 | |
| QQQQQQQQQQQQQQQ | 156 | O15409 | |
| QQQQQQQQQQQQQQQ | 161 | O15409 | |
| QQQQQQQQQQQQQQQ | 166 | O15409 | |
| QQQQQQQQQQQQQQQ | 171 | O15409 | |
| QQQQQQQQQQQQQQQ | 176 | O15409 | |
| LQQQQQQQQQQQQQQ | 246 | Q96RN5 | |
| QQQQQQQQQQQQQQQ | 2051 | Q93074 | |
| QQQQQQQQQQQQQQQ | 2056 | Q93074 | |
| QQQQQQQQQQQQQQQ | 2061 | Q93074 | |
| QQQQQQQQQQQQQQQ | 2091 | Q93074 | |
| QQQQQQQQQQQQQQQ | 2096 | Q93074 | |
| QQQQQQQQQQQQQQQ | 2101 | Q93074 | |
| QQQQQQQQQQHQQQQ | 2106 | Q93074 | |
| QQQQQQQQQQQQQQQ | 61 | P10275 | |
| QQQQQQQQQQQQQQQ | 66 | P10275 | |
| QQQQQQQQQQQQQQQ | 1251 | O94916 | |
| QQQQQQQQQQQQQQQ | 591 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 596 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 601 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 606 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 641 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 646 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 651 | Q8IZL2 | |
| QQQQQQQQQQQQQQQ | 261 | Q14686 | |
| QQQQQQQQQQQQQQQ | 266 | Q14686 | |
| QQQQQQQQQQQQQQQ | 271 | Q14686 | |
| QQQQQQQQQQQQQQQ | 21 | P42858 | |
| QQQQQQQQQQQQQQQ | 1751 | Q5JV73 | |
| QQQQQQQQQQQQQQQ | 1756 | Q5JV73 | |
| QQQQQQQQQQQQQQQ | 1761 | Q5JV73 | |
| MQQQQQQQQQQQQQQ | 1 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 6 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 11 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 16 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 21 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 26 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 31 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 36 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 41 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 46 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 51 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 56 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 61 | Q156A1 | |
| QQQQQQQQQQQQQQQ | 896 | O75064 | |
| QQQQQQQQQQQQQQQ | 526 | Q10571 | |
| QQQQQQQQQQQQQQQ | 531 | Q10571 | |
| QQQQQQQQQQQQQQQ | 536 | Q10571 | |
| QQQQQQQQQQQQQQQ | 51 | Q13950 | |
| QQQQQQQQQQQQQQQ | 56 | Q13950 | |
| QQQQQQQQQQQQQQQ | 216 | P51531 | |
| QQQQQQQQQQQQQQQ | 221 | P51531 | |
| QQQQQQQQQQQQQPQ | 226 | P51531 | |
| QQQQQQQQQQQQQQQ | 1251 | Q9Y6Q9 | |
| QQQQQQQQQQQQQQQ | 1256 | Q9Y6Q9 | |
| QQQQQQQQQQQQQQQ | 1261 | Q9Y6Q9 | |
| QQHQQQQQQQQQQQQ | 126 | P20265 | |
| QQQQQQQQQQQQQQQ | 131 | P20265 | |
| QQQQQQQQQQQQQQR | 136 | P20265 | |
| QIQQQQQQQQQQQQQ | 591 | Q01826 | |
| QQQQQQQQQQQQQQQ | 501 | Q8TF68 | |
| KQQQQQQQQQQQQQQ | 336 | Q14119 | |
| QQQQQQQQQQQQQQH | 341 | Q14119 | |
| QQQQQQQQQQQQQQP | 191 | Q8WV24 | |
| QRQQQQQQQQQQQQQ | 56 | P20226 | |
| QQQQQQQQQQQQQQQ | 61 | P20226 | |
| QQQQQQQQQQQQQQQ | 66 | P20226 | |
| QQQQQQQQQQQQQQQ | 71 | P20226 | |
| QQQQQQQQQQQQQQQ | 76 | P20226 | |
| QQQQQQQQQQQQQQQ | 81 | P20226 | |
| QQQQQQQQQQQQQQP | 426 | P78364 | |
| KQQQQQQQQQQQQQQ | 1461 | Q68DE3 | |
| QQQQQQQQQQQQQQQ | 106 | Q96EK4 | |
| QQQQQQQQQQQQQQQ | 111 | Q96EK4 | |
| QQQQQQQQQQQQQQQ | 116 | Q96EK4 | |
| QQQQQQQQQQQQQQQ | 1726 | Q15911 | |
| QQQQLQQQQQQQQQQ | 3951 | O14686 | |
| QQQQQQQQQQFQQQQ | 3956 | O14686 |